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Abstract
The Aryl hydrocarbon Receptor (AhR) is a ligand-activated transcription factor
best known for its role in xenobiotic metabolism of environmental pollutants. Activation
of the AhR by its prototypical ligand 2,3,7,8-tetrachlorodibenzo-pdioxin (TCDD) leads to
pronounced thymic atrophy and severe immunosuppression. Studies of AhR activation
can have dual applications: to better understand AhR-mediated immunotoxicity and to
harness its immunomodulatory effects for therapeutic use. Here, we first aimed to
determine whether AhR-mediated thymic atrophy was ligand-dependent through the use
of dietary and endogenously sourced ligands, indole-3-carbinol (I3C) and 2-(19 Hindole-39 -carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE) respectively. We also
aimed to identify key mediators of TCDD-induced thymic atrophy through the use of
lineage-specific Cre-lox conditional knockout mice. We hypothesized that AhR
activation induces thymic atrophy in a ligand-dependent manner and AhR expression
within CD11c+ DCs is necessary for thymic atrophy by TCDD. In vivo exposure of ITE
and I3C yielded dramatically different thymic outcomes with ITE resulting in severe
thymic atrophy similar to TCDD while I3C did not induce atrophy. Through the use of
Cre-Lox conditional knockout mice under lineage-specific promoters, we identified a
requisite role for AhR activation in CD11c+ cells for TCDD-induced thymic atrophy.
We next aimed to apply current understanding of AhR-mediated immune suppression in
the development of a liposomal nanoparticle (LNP) delivery system for concentrated
delivery of AhR-agonist, ITE, to dendritic cells. Dendritic cells are exquisitely sensitive
to AhR activation and promote the generation of regulatory T cells. ITE is a potent
inducer of AhR activation; however, it is rapidly metabolized and systemic exposure to
high doses can have undesirable effects. Therefore, we hypothesized that the generation
and delivery of AhR agonist-loaded liposomal nanoparticles would activate the AhR in
dendritic cells leading to a phenotype similar to TCDD, and result in cell-specific uptake
when administered in vivo. LNP maintained high ITE entrapment, were of optimal size
for dendritic cell uptake, induced AhR-responsive genes in vitro, and were preferentially
taken up by splenic APCs. Together, this work furthers our understanding of AhRmediated thymic atrophy, and presents a novel AhR agonist delivery system for
therapeutic application of the AhR.
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CHAPTER 1: INTRODUCTION
This study describes the effects of aryl hydrocarbon receptor (AhR) activation on
the thymus. Chapter 1 will: 1) introduce the AhR and its numerous ligands, 2) introduce
the basic structure of the thymus and its role as a primary immune organ and 3) describe
dendritic cells and their basic role within the immune system.

THE ARYL HYDROCARBON RECEPTOR
DISCOVERING THE AHR
While multiple scientific advances coalesced into the discovery of the Aryl
hydrocarbon Receptor (AhR), a common theme existed; namely the necessity to
understand mechanisms of xenobiotic toxicity. Specifically, the discovery that
polycyclic aromatic hydrocarbons (PAHs) appeared to induce their own metabolism
drove the ultimate discovery of a receptor that could bind these compounds. First
described by Allan Conney in the 1950’s, and originally termed the BP hydroxylase,
due to its induced expression following exposure to benzo(a)pyrene (BaP), the
receptor’s name was broadened to Aryl hydrocarbon Hydroxylase (AhH) in the 1970’s
with the discovery that multiple PAHs were suitable ligands (Figure 1.1) (Okey et al.
1979; Wright et al. 2017; Yao and Denison 1992).
Up until the late 1970’s, the AhR was still seen as a hydroxylase that was acted on
by a receptor; the AhR itself being identified as a receptor had not yet come to fruition. A
monumental contribution to AhR research came with the discovery that 2,3,7,8
tetrachlorodibenzo-p-dioxin (TCDD), a halogenated aromatic hydrocarbon, could bind
mammalian hepatocytes (Kouri et al. 1974). Following this discovery, TCDD was also
determined to induce metabolism in tissues and systems previously found unable to do so
with PAHs. These landmark studies enabled the ultimate identification of an “induction
receptor” in 1976 by Poland, Glover, and Kende (Harper et al. 2006). Soon after, the
receptor was termed Ah Receptor after Okey and Nebert documented its receptor-like
activity (Wright et al. 2017; Yao and Denison 1992). Formally known as the Aryl

hydrocarbon Receptor, and with its prototypical ligand discovered, AhR research and its
impacts across multiple disciplines, including immunology, were just beginning.

Figure 1. 1 AhR Timeline of Discovery

Renamed Aryl hydrocarbon
Hydroxylase (AhH) after it was found
to be induced by a broad range of
chemicals (Nebert & Bausserman).
AhH expression was necessary for
toxic effects of PAHs.

1950
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In Vivo experiment in mice and
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as a key observation after AhR
activation by PCBs. AhR is
expressed for 2x as long in
thymus as non-immune tissues

1984

Present

Renamed Aryl
22 years of AhR research within
hydrocarbon Receptor
the immune system
(AhR) after it was found to
not only be induced, but
to directly bind chemicals
(Okey & Nebert)

Figure 1. 1 AhR Timeline of Discovery
A brief timeline of key events that led to the discovery of the AhR and AhR research in
the field of immunology.
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AHR SIGNALING PATHWAYS
The AhR is a cytosolic, ligand-activated transcription factor in the basic helixloop-helix/Per-Arnt-Sim (bHLH/PAS) protein family. In mammals, the AhR is
ubiquitous with temporal, cellular, and tissue-specific expression. Greatest AhR
expression occurs in the liver, thymus, lung, kidney, spleen, and placenta (Harper et al.
2006). Studies have shown that the AhR plays important roles beyond xenobiotic
metabolism, including roles in hematopoiesis, immune system biology, neural
differentiation, and liver formation (Wright et al. 2017).
In its inactive state, the AhR is found in the cytosol complexed to a host of
chaperone proteins including XAP2, HSP90, and AIP. Upon ligand binding, a
conformational change releases the chaperone proteins and exposes the nuclear
localization sequence (Figure 1.2). The ligand:AhR is transported into the nucleus
where it heterodimerizes with another bHLH/PAS protein, the Aryl hydrocarbon
Receptor Nuclear

Transporter (ARNT,

HIF1β)

(Yao

and

Denison

1992).

Ligand:AhR/ARNT complexes specifically recognize and bind dioxin/xenobiotic
responsive elements (DRE/XRE) in the promoter region of AhR-inducible genes
(Dolwick et al. 1993). The mere presence of the DRE consensus sequence, 5'TNGCGTG-3', upstream of a gene can be used to determine whether the gene is AhRresponsive, and most AhR-responsive genes have multiple DRE in the promoter region
(Swanson et al. 1995).
The most common and consistent transcriptional target of the AhR canonical
pathway following TCDD exposure is Cytochrome P450, family 1, subfamily A,
polypeptide 1 (Cyp1a1), a phase I metabolizing enzyme. Within the promoter region of
murine Cyp1a1, there are eight putative DREs and five of these are conserved between
mouse, rat, and human (Li et al. 2014; Nukaya and Bradfield 2009). Therefore,
measuring Cyp1a1 gene expression is both an accurate and a translational readout of
AhR activation. Importantly, the AhR transcribes a host of other genes with cell/tissue
specificity including indoleamine-2,3 dioxygenase 1 and 2 (IDO 1 and 2), isoforms of
transforming growth factor beta (TGFβ), and retinaldehyde dehydrogenases (RALDH)
(Vogel et al. 2008).
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Having discussed the AhR canonical pathway, it is necessary to briefly address
the AhR non-canonical pathway, which is also shown in Figure 1.2. The AhR noncanonical pathway occurs through alternative binding of nuclear AhR independent of
ARNT and can result in expression of genes needed to maintain homeostasis (Wright
et al. 2017). Less is currently understood regarding the interactions and implications of
the non-canonical pathway.
Figure 1. 2 AhR signaling pathways.

Figure 1.2 AhR signaling pathways.
A diagram of protein interactions involved in the AhR canonical and non-canonical
signaling pathways. In the canonical AhR signaling pathway, a ligand diffuses into the
cell and binds cytosolic AhR complex, which triggers dissociation of chaperone proteins.
The ligand-bound AhR translocates to the nucleus where it binds ARNT enabling binding
to canonical DREs and triggering transcription of the AhR gene battery. In the noncanonical signaling pathway, the ligand-bound, nuclear AhR binds proteins independent
of ARNT. RelB in the nucleus thereby allows binding to NF-kB response elements.
(Wright et al. 2017)
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AHR ALLELES
In the early years of AhR research, there were conflicting results regarding
protein and ligand binding, which can now be attributed to the use of mouse strains with
different AhR alleles. These alleles include AhR b-1, AhRb-2, AhRb-3, and AhRd (Smith et
al. 2018). C57Bl/6 mice carry the best-studied allele: AhR b-1, which readily binds TCDD
with high affinity. DBA/J mice, however, carry the AhRd allele with a 10x lower binding
affinity for TCDD due to an alanine375 to valine substitution in the ligand-binding domain
(Ema et al. 1994). Additionally, the AhR demonstrates both basal and inducible
expression that is dependent on tissue and cell type. In mammals, organs known to have
the highest basal AhR expression levels include the liver, lung, kidney, spleen, placenta,
and thymus (Harper et al. 2006). Within the immune system, AhR is expressed basally by
a majority of cells types, and increased AhR expression occurs with exposure to
xenobiotics, mitogens, antigens, and cytokines (Pohjanvirta 2011)
Importantly, AhRb-1 mouse models have so far been the predominant source for
our current understanding of the AhR, but there are differences between the AhR b-1 allele
expressed in mice and the AhR expressed in most humans, which share 85% sequence
homology. The human AhR binds to TCDD more similar to the AhR d mouse allele with
~10x lower affinity than murine AhRb-1. Interestingly, human AhR has a similar mutation
to murine AhRd with an amino acid substitution in the ligand-binding domain, and some
research suggests that the human AhR may bind endogenous compounds with greater
affinity than exogenous compounds (Hubbard et al. 2016).
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AHR LIGANDS
While TCDD is the prototypical AhR ligand, due to its high binding affinity,
numerous compounds are known to bind and activate the AhR. AhR ligand interactions
that are best understood involve planar, hydrophobic, highly toxic environmental
compounds within the halogenated aromatic hydrocarbons (HAHs) and polycyclic
aromatic hydrocarbons (PAHs); however, the increased interest in AhR in multiple fields
has resulted in a continual identification of AhR ligands beyond the classical, exogenous
HAHs.
Classical ligands do not vary far from the prototypical AhR ligand, TCDD, and
generally take planar conformations with multiple benzene rings and act as AhR agonists.
Importantly, a broad range of non-classical ligands, those that vary substantially from
TCDD, can readily bind the AhR (Figure 1.3)(Pohjanvirta 2011). Notably, compounds
with demonstrated antagonistic properties also directly bind the AhR, and can result in
ligand-selective antagonism. Notably, 2-methyl-2H-pyrazole-3-carboxylic acid (2methyl-4-o-tolylazo-phenyl)-amide (CH223191) can block binding of TCDD and other
halogenated aromatic hydrocarbons (HAH), without blocking binding of non-HAH
ligands (Pohjanvirta 2011).
While TCDD is an exogenous compound, endogenous compounds have also been
identified. The earliest and arguably most notable is 2-(1′H-indole-3′-carbonyl)-thiazole4-carboxylic acid methyl ester (ITE), which was isolated from porcine lungs in 2002, and
found to bind AhRb with moderate affinity (3nM ITE vs .27nM TCDD) (Song et al.
2002). The identification of an endogenous ligand was a pivotal finding as the AhR is a

6

highly conserved protein and its roles in xenobiotic metabolism and immune modulation
are likely more recent adaptive functions.
Diet is a prominent source of AhR ligands—from both bioaccumulation of TCDD
in fatty tissue of animals and from plant-derived ligands such as Indole-3-carbinol (I3C).
In fact, one study analyzing body burden of TCDD-equivalents (TEQs) found plant-based
dietary ligands to be a greater contributor (96% of TEQ) than TCDD to total body burden
in humans (Connor and Finley 2003). Notably, ligand affinity, an important factor, was
not addressed in this analysis, but it highlights the need to study a variety of ligands
beyond TCDD, including those from dietary sources.
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Figure 1. 3 A representative panel of AhR ligands

Figure 1.3 A Representative Panel of AhR ligands.
A panel of known AhR ligands intended to show their variation and similarity
(Denison and Nagy 2003).
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AHR-INDUCED IMMUNOSUPPRESSION
In 1984, thymic expression of the AhR in Sprague-Dawley rats was determined to
occur at high levels for twice as long (42 days vs. 21 days) after parturition as compared
to non-immune tissues such as liver and lungs (Nikolaidis et al. 1988). These
observations led to further investigation of AhR activity in immune organs, and the
discovery that AhR activation had adverse effects on thymic function. In 1985, PCBs
acting through the AhR were found to cause severe thymic atrophy and humoral immune
suppression (Hanieh 2014). The succession of rapid discoveries throughout the 1980s
broadened the expanse of AhR-mediated suppression within the immune system to
include: reduction in splenic lymphocyte number and function in mice, reduced humoral
antibody response in mice and rats, and overall reduction in ability of mice to fight
certain infections (Goudot et al. 2017).
With a potential link made between the AhR and observed suppression of the
immune system, immunologists entered into a field, which to this point had
predominantly been pioneered by toxicologists and biochemists. The interweaving of
discoveries from these disciplines has both expanded our understanding of the AhR
signaling pathway and of the immense complexity of the innate and adaptive immune
responses.
Innate immune cells strongly vary in AhR expression (Figure 1.4), ranging from
high, constitutive expression, to low, conservatively inducible expression. The outcome
of AhR activation on promotion or regulation of immune responses also appears to vary
by cell type and maturation phase. Interestingly, both inflammatory and regulatory genes
have an abundance of AhR responsive elements within their promoter regions, and it has
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been shown that cross-talk between AhR and NF-B results in multiple pro-inflammatory
signals (Goudot et al. 2017). Neutrophils, and most granulocytes are not thought to
express the AhR at significant levels and appear to be predominantly influenced by AhR
activation through an indirect mechanism.
Antigen presenting cells, macrophages and dendritic cells, constitutively express
the AhR at relatively high levels and show further AhR expression upon activation and
maturation (Kreitinger et al. 2016). It has also been shown in vitro that AhR activation in
monocytes selectively promotes differentiation of murine monocyte-derived DCs through
induction of BLIMP-1 (Goudot et al. 2017), while impairing differentiation of monocytederived Macs. Additionally, AhR deficiency correlated with a reduced frequency of
monocyte-derived DCs in vivo (Goudot et al. 2017). Dendritic cells are highly responsive
to AhR activation and demonstrate AhR-mediated alterations to maturation, protein
expression, and gene induction. Specifically, AhR activation results in an increase in
immature dendritic cells as marked by moderate CD11c and MHII expression. AhRactivated dendritic cells show increased frequency and density of co-stimulatory
molecules as well as increased expression of regulatory genes, including Indoleamine
2,3-dioxygenase-1,-2 (IDO-1,-2) and transforming growth factor beta (TGF). AhRinduced regulatory DCs are potent inducers of Foxp3+ regulatory T cells, while direct
exposure of naïve T cells to AhR activation appears to induce non-Foxp3+ Tregs
(Bankoti et al. 2010c; Benson and Shepherd 2011b; Gagliani et al. 2015; Qiu et al. 2012).
Natural killer cells, which are thought to have basal expression of AhR, are
reported to have reduced bacterial clearance and tumor cell recognition capacity in AhR -/mice. These studies also suggest that NK cells are, in part, directly affected by AhR
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activation with a modest immune enhancement function (Winans et al. 2015).
Conversely, there are also reports showing AhR-mediated immunosuppressive NK cell
function, which suggests that additional environmental, or maturational components may
be involved in AhR-mediated effects on NK cells (Kreitinger et al. 2016).
Innate lymphoid cells (ILCs), which play an important role in mucosal immunity,
were shown to have compromised bacterial clearance through reduced IL-22 expression
when ILCs lacked AhR (Pearse 2006). While AhR research in ILCs is relatively minimal,
current literature suggests AhR activation in ILC subsets may be necessary for infection
clearance within mucosa. AhR impacts CD4+ T cell subsets, both directly and indirectly,
to different ends; variation in AhR expression levels is a probable explanation. Th1 and
Th2 cells, which are thought to have minimal AhR expression, show AhR-mediated
immune deviation. Specifically, Th1 cells become the dominant subset over Th2 cells
through GATA binding protein-3 (GATA-3) inhibition in naïve T cells (Kreitinger et al.
2016). Th17 cells, which are known to express high levels of AhR, are shown to undergo
rapid expansion upon direct AhR activation. Interestingly, with influences from AhR
activation and subsequent TGF signaling, new research shows that inflammatory Th17
cells can undergo transdifferentiation to Tr1 cells, a Foxp3- regulatory T cell subset
(Pearse 2006). CD4+ Foxp3+ regulatory T cells (Tregs) moderately express the AhR, and
AhR activation in DCs significantly increases regulatory T cell frequency and effector
functions indirectly (Kreitinger et al. 2016). Within CD8+ T cells, recent discoveries
have found that AhR activation by xenobiotics during development has long-lasting
effects on CD8+ frequencies through an epigenetic mechanism, ultimately reducing
antiviral capacities (Pearse 2006). At this time, AhR expression in B cells is not well
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understood. It has been documented by numerous studies that AhR activation by
xenobiotics reduces antibody production and overall humoral immunity; however, it has
not been determined whether this reduction in humoral immunity is due to direct AhR
activation in B cells. Altered antibody production has been associated with both CD4+ T
cell and DC AhR activation.

Figure 1. 4 AhR Expression in Immune Cells

Figure 1.4 AhR Expression in Immune Cells.
AhR expression (x-axis) and outcomes of AhR activation (y-axis) by immune cell type.
Importantly, AhR expression by cell type is based on mRNA and not protein expression.
(Kreitinger et al. 2016)
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THE THYMUS
A PRIMARY IMMUNE ORGAN
The thymus is a multi-lobed primary immune organ that rests directly above the
heart. The thymus and bone marrow compose the mammalian primary immune organs
with important roles in development, differentiation, and education of competent immune
cells. From primary immune organs, immature immune cells seed most tissues of the
periphery including secondary lymphoid tissues such as the spleen and lymph nodes, sites
of mucosa, and skin to form the innate and adaptive immune systems.

STRUCTURE AND ORGANIZATION
Both hematopoietic and non-hematopoietic cells constitute the thymus. Stromal
elements including epithelial cells and fibroblasts, as well as dendritic cells, organize the
thymus into two functionally distinct microenvironments: cortex and medulla (Figure
1.5). The cortex, which is the more outer tissue of the thymus, has a high cellular density
predominantly composed of small, immature thymocytes (Murphy and Weaver 2016;
Pearse 2006). The cortex is an area of rapid cell division and cell death with lymphoblasts
undergoing mitosis and large numbers of thymocytes undergoing apoptosis. There are
relatively low numbers of epithelial cells in the cortex and relatively high numbers of
macrophages in order to phagocytize apoptotic bodies (Murphy and Weaver 2016; Pearse
2006).
The medulla is the more central portion of the thymus and has a lower cell density
than the cortex (Murphy and Weaver 2016; Pearse 2006). Cells that have passed the first
stage of selection, discussed in detail below, will migrate to the medulla where they
13

interact with dendritic cells and medullary thymic epithelial cells (mTECs) and undergo
the second stage of selection. Cells undergo turnover much less rapidly than in the cortex
and will leave the medulla as fully functional naïve T cells.

Figure 1. 5 Thymus Organization.

Figure 1.5 Thymus Organization.
A diagram of thymic organization and thymocyte development. (Blackburn and Manley 2004)
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T CELL SELECTION
T cells, a key component of adaptive immune responses, are produced in the
thymus. Once in the thymus, CD3-, T cell Receptor- (TCR), CD4-/CD8- (doublenegative, DN) lymphoid precursors interact with thymic stroma and undergo necessary
commitment to either
the αβ or λδ T cell lineage through TCR gene rearrangement. αβ T cells, which compose
a majority of thymocytes, undergo strict selection events that can be tracked by surface
protein expression of CD4 and CD8 co-receptors (Figure 1.6) (Savino 2006).
First, CD4+ CD8+ thymocytes (double-positive, DP), which make up a majority
of thymocytes, undergo positive selection in the cortex where only cells with TCRs that
can recognize self-peptide:self-MHC presented by cortical epithelial cells (cTECs) will
survive. Most cells do not express receptors that can recognize self-peptide complexes
and therefore most DP thymocytes die. Cells that have successfully passed positive
selection will undergo negative selection, which occurs in the medulla and is facilitated
by medullary epithelial cells (mTECs) and dendritic cells (DCs), to ensure that they do
not recognize self antigens too strongly. A small niche of self-recognizing thymocytes is
not negatively selected, but instead is driven toward a regulatory phenotype leading to
thymic Tregs.
Cells that fail negative selection undergo programmed cell death, and are
predisposed to Bim-mediated apoptosis. For the ~2% of cells that successfully navigate
positive and negative selection, down-regulation of either CD4 or CD8 corresponds with
the cell’s ability to recognize extracellular antigen bound to MHC II or self-peptides
bound to MHCI, respectively (Murphy and Weaver 2016). These successfully
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recombined CD4+ or CD8+ single positive (SP) naïve T cells will then leave the thymus
to seed the periphery. Overall, these critical selection events ensure only centrally tolerant
and functional, immature T cells develop. Unlike αβ T cells, γδ T cells are a distinct but
minor lineage that does not undergo positive and negative selection. Some γδ T cell
receptors may recognize antigen directly, in a way similar to antibodies, and are not
restricted to antigen presented on Major Histocompatibility Complexes (MHC) like αβ T
cells. γδ T cells are currently not well studied, but it is understood that γδ T cells leave
the thymus to seed peripheral tissues, such as the dermis, in waves or bursts that
correspond with development (Murphy and Weaver 2016).
Figure 1. 6 Thymocyte Maturation.

Figure 1.6 Thymocyte Maturation.
Diagram of thymic selection where thymocytes transition from CD4/CD8 double
negative (DN) to double positive (DP) to single positive (SP) (Savino et. al, 2006).
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THYMIC ATROPHY
Thymic atrophy is the severe shrinking of thymic tissue and occurs for a variety
of reasons. Age-related thymic atrophy is considered a natural process where the thymus
begins a slow, steady decline after adolescence. Numerous studies suggest that agerelated thymic atrophy is due to alterations in the stromal compartment, predominantly
epithelial cells, and corresponds with reduced Foxn1, a transcriptional regulator
necessary for thymic epithelial cell (TEC) development (Cepeda and Griffith 2017;
Lepletier et al. 2015; Masters et al. 2017). Interestingly, during age-related thymic
atrophy, thymic tissue is replaced by an increased deposition of adipose tissue (Cepeda
and Griffith 2017).
Age-related thymic atrophy decreases thymic output of naïve T cells, which leads
to a narrowing of peripheral TCR repertoires (Murray et al. 2003; Surh and Sprent 2000).
As fewer naïve T cells are produced within the aged thymus, the periphery continues to
expand peripheral T cells, which leads to a skewed ratio of naive T cells to memory T
cells. Consequently, the reduced output of naïve T cells and corresponding expansion of
peripheral T cells leads to a systemic reduction in the diversity of TCR repertoires over
time.
Notably, T cell output by an aged thymus is not completely inhibited, but naïve T
cells that are successfully formed exhibit a high potential for senescence, marked by
increased CD57 expression, and show a limited response upon exposure to antigenic
stimuli (Mo et al. 2003). Additional phenotypic differences in naïve T cells generated by
aged-thymi include reduced CD62L, a lymph node-homing protein and the chemokine
CCR7, which suggests these T cells may not properly mobilize to relevant lymphoid
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tissues (Haynes and Swain 2006). Together, these alterations would lead to defective
responses to primary antigen exposures, such as new pathogens or vaccinations, as well
as novel, endogenous tumor antigens.
Conversely, aged-thymi are also associated with autoimmune diseases that
develop in geriatric patients (Prelog 2006). As previously discussed, the thymus strictly
selects against self-reactive T cells prior to their entry into the periphery, a process
largely controlled by thymic DCs and TECs; however, these stromal cell populations
undergo substantial loss during age-induced atrophy, resulting in an increase in autoreactive T cell escape, and ultimately a weakening of central tolerance corresponding
with chronic inflammation (Coder et al. 2015).
Importantly, aging is not the only factor able to induce thymic atrophy. In fact,
periodic and stochastic thymic atrophy can occur from infection, pharmaceuticals,
including chemotherapies and high-dose antibiotics, some cancers and tumors,
pregnancy, and exposure to toxicants such as TCDD (Cepeda and Griffith 2017). These
forms of thymic atrophy appear to differ from, and may exacerbate, age-related thymic
atrophy in that they are often transient with partial recovery/regeneration occurring once
the contributing factor or insult is removed.

AHR AND THYMUS
The thymus expresses high levels of AhR (Carlstedt-Duke 1979) and thymic
atrophy by TCDD was first noted in a 1970’s study where multiple laboratory rodent
species were exposed to TCDD via gastric intubation (Harris et al. 1973; Poland and
Glover 1975). It was a key study in the 1980’s that connected AhR activation to the
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drastic alterations of a primary immune organ, becoming a key turning point in AhR
research that peaked the interest of immunotoxicologists. Additionally, thymic atrophy
and nutmeg liver became hallmark signs of exposure to exogenous AhR ligands, and it
was long thought that the profound suppression of T cell-mediated immune responses
was in part due to disrupted T cell development within the atrophied thymus.
Immunological studies assessed alterations to thymic cells in adult mice, as well
as in utero and in vitro fetal thymic cultures (Esser and Welzel 1993; Holladay et al.
1991; Lutz et al. 1998; Poland and Glover 1975). These studies determined that the
thymus was directly affected by TCDD, predominantly through a significant depletion of
CD4+CD8+ double positive (DP) thymocytes (Esser and Welzel 1993; Holladay et al.
1991; Silverstone et al. 1994b). This loss of DP thymocytes was believed, at the time, to
underlie the profound suppression of peripheral T cell responses following exposure to
TCDD and dioxin-like compounds.
Interestingly, while TCDD-induced thymic atrophy is largely due to a loss of DP
thymocytes, developing thymocytes have relatively low basal AhR expression as
measured through mRNA, suggesting the DP loss is an indirect effect of AhR activation
(Figure 1.7). Importantly, hematopoietic and non-hematopoietic cells constitute the
thymus, and thymic precursors seed the thymus from bone marrow. Studies suggested
that TCDD affected thymocytes from bone marrow (Silverstone et al. 1994b); however,
the contributions of AhR expression within hematopoietic and non-hematopoietic cells
remained a key question.
Staples et al. (1998) performed bone marrow chimera studies where they
irradiated AhR+ mice and AhR-/- mice to deplete bone marrow derived cells. Chimeras
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were created with AhR+ mice receiving AhR-/- bone marrow, and AhR-/- mice receiving
AhR+ bone marrow prior to TCDD exposure. Interestingly, only mice that had AhR
expression in bone marrow underwent thymic atrophy. This key finding determined that
AhR expression in hematopoietic cells was necessary to induce thymic atrophy following
TCDD exposure. Notably, the hematopoietic compartment is highly heterogeneous
(Figure 1.7) and a key question that has remained unanswered since these early studies is
whether AhR expression within specific cell types of the hematopoietic compartment is
responsible for thymic atrophy.
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Figure 1. 7 AhR Expression within the hematopoietic compartment.

Figure 1.7. A diagram of AhR expression in cells of the hematopoietic compartment
(Esser and Rannug 2015) . Shades of blue represent AhR expression potential
consolidated from studies using qPCR and Western blot analysis. Plus signs (+)denote
cells where AhR activation has been described to alter the function of the cell. Asterisks
(*) denote cells in which AhR is suggested to play a role in lineage-specific
differentiation.

21

DENDRITIC CELLS

PROFESSIONAL ANTIGEN PRESENTING CELLS
Just as research in the 1970’s was leading to the discovery of the AhR, research
by Ralph Steinman during this time was leading to the identification of dendritic cells
(DCs) (Merad et al. 2013). DCs are described as professional antigen-presenting cells for
their ability to phagocytize, internally process, and present antigen bound to surface
proteins called major histocompatibility complexes (MHC). In mice, MHCI are loaded
with short peptides derived from intracellular proteins while MHCII are able to
accommodate slightly longer peptides from extracellular proteins. These antigen:MHC
complexes act as a key form of communication between DCs and T cells.
According to the three-signal hypothesis (Figure 1.8), DCs employ cognate and
soluble interactions to orchestrate three key signals when communicating with T cells
(Kambayashi and Laufer 2014). First, peptide-loaded MHC on the surface of DCs
interact with T cell receptor (TCR) complexes. Second, surface proteins on the DCs
including CD80 and CD86 or CD40, interact with CD28 or CD40L on the T cell to
provide co-stimulatory signals. Last, cytokines produced by dendritic cells act as soluble
instructors to influence the fate and response of antigen-specific T cells. Together, these
interactions result in both positive and negative signaling cascades in the T cells that
ultimately result in differentiation, cellular proliferation, and/or activation-induced cell
death. This emphasizes the critical role that DCs play in T-cell differentiation,
homeostasis, activation, acquisition of effector functions, and apoptosis.
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Together, T cells and dendritic cells interact with B cells to promote antigenspecific antibody responses through B cell proliferation and isotype (class) switching.
While B cells can recognize soluble antigens independently of dendritic cells, the
presentation of antigen by dendritic cells is crucial for the development of efficient
humoral responses. AhR activation has long been shown to disrupt humoral immune
responses, predominantly through reduced IgG expression. Interestingly, IgA expression
is enhanced with AhR activation and some of our work that has been previously
presented, but not to be discussed at length in this dissertation, suggests the effects on Ig
secretion is, in-part, due to AhR activation within dendritic cells.
Figure 1. 8 The Three-signal Hypothesis

Figure 1. 8 The Three-signal Hypothesis. Within this hypothesis, signal 1 is formed by the
cognate interactions of MHC on dendritic cells with TCR and TCR co-receptor on T cells. Signal
2 is also a cognate interaction between co-stimulatory molecules including CD40-CD40L,
CD80/86-CD28/CD3, while signal three includes soluble factors including cytokines such as
inflammatory IL-12 or inhibitory IL-10. (Kambayashi and Laufer 2014)
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DIVERGENT FUNCTIONS OF DCS
DCs can acquire diverse activation, maturation, and functional states that
correspond with a dichotomy in immune responses (Figure 1.9). Stimulatory, or
inflammatory DCs, release inflammatory cytokines including IFNγ, TNFα, and IL-6 to
drive inflammatory T cell responses required for protection against pathogens and
tumors. However, aberrant stimulatory DC presence can promote the development of
autoimmune pathologies. Conversely, DCs can adopt a regulatory phenotype through
signals within their microenvironment, such as TGFβ, IL-10, or compounds that bind and
activate the AhR. Regulatory DCs play an important role in organ homeostasis through
inhibition of T cell activation and promotion of regulatory T cell differentiation and/or
maintenance and provide a promising potential route for therapeutic immune suppression.
Figure 1. 9 Divergent DC Functions

Figure 1.9 Divergent DC Functions
Diagram depicting signal integration in immature DCs and subsequent stimulatory
versus regulatory DC outcomes. Schmidt et al., 2012. Frontiers in Immunol. 3
(274); 1-17.
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DCs IN THE THYMUS
DCs play another key role in the formation of the adaptive immune system
through interactions with developing thymocytes in the thymus. In mice, hematopoietic
DCs, which share a common lineage marker, CD11c, can be divided into numerous
subsets dependent on tissue and location. Within the thymus, DC populations consist of
conventional DCs (cDCs) and plasmacytoid DCs (pDCs). Studies using parabiotic mice
congenic for CD45.1 or CD45.2 established that thymic cDCs can be subdivided into two
populations with different developmental origins. Resident, thymus-derived cDCs
(cDC1), identified by expression of CD11c+ CD8α+ Sirpα-, arise from precursors within
the thymus. Migratory cDCs (cDC2) identified by expression of CD11c+CD8α- Sirpα+,
are present in circulation prior to seeding the thymus (Proietto et al. 2008a).
cDC1 and cDC2 were shown to be equally competent at performing negative
selection of DP thymocytes while plasmacytoid DCs were not as effective at negative
selection (Atibalentja et al. 2011). cDC2 may participate in thymic selection through
presentation of processed antigen taken up while in the periphery, or by transfer of
peptides from cDC1 and thymic epithelial cells once they have migrated into the thymus
from the periphery (Allan et al. 2006; Atibalentja et al. 2011; Knight et al. 1998).
Additionally, both thymic cDC1s and sDC2s show an ability to induce CD4+ CD25+
Foxp3+ regulatory T cells (Tregs) from naïve T cells in culture (Proietto et al. 2008a).

AhR AND DC
Of immune cells with AhR mRNA levels currently characterized, DCs are
considered to be one of the highest expressers (Figure 1.4 and 1.7) (Esser and Rannug
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2015). AhR activation in DCs by TCDD is associated with alterations to antigen
presentation and costimulatory molecules, including ICAM-1, CD24, CD86, and CD40
(Vorderstrasse and Kerkvliet 2001). Steady-state DCs, a term for DCs cultured in vitro
with granulocyte macrophage-colony stimulating factor (GM-CSF) instead of Flt3ligand, showed reduced MHC class II, CD86, CD80, and CD54 and were associated with
increased generation of CD4+ Foxp3+ Tregs in vitro (Simones and Shepherd 2011) .
Dietary compounds, indole-3-carbinol (I3C) and indirubin-3-oxime (IO) were
found to reduce expression of CD40, CD54, and CD11c while increasing MHCII and
CD80 on murine CD11c+ DCs in vitro. These dietary compounds also altered gene
expression with increased mRNA for genes, including ALDH1A, IDO, and TGFβ. These
genes code for proteins that are able to metabolize available tryptophan, reducing its
availability for proliferating immune cells and initiating class switching of antibody
isotypes, and are implicated in the regulatory DC phenotype and the generation of
regulatory cells (Quintana et al. 2010c). These dietary compounds also reduced DC
production of pro-inflammatory cytokines: tumor necrosis factor alpha (TNFα), IL-1β,
IL-12, and IL-6 while increasing IL-10 protein levels (Benson and Shepherd 2011b).
Importantly, unlike TCDD, the effects of dietary ligands were partially mediated by the
AhR (Benson and Shepherd 2011b) .
While these effects of AhR activation were observed in steady-state DCs
(Simones and Shepherd 2011), it was also necessary to determine whether these effects
could occur in DCs within an inflammatory environment. In vitro generation of
inflammatory DCs exposed to LPS or CpG showed marked reduction in inflammatory
signaling when exposed to TCDD (Bankoti et al. 2010a; Bankoti et al. 2010b).

26

Importantly, AhR expression and consequences of AhR activation in murine DCs is
highly translational as AhR expression occurs at high levels in human DCs and human
DCs exposed to AhR agonists lead to suppressed T cell responses through reduced Th1
and Th17 polarization (Platzer et al. 2009; Wang et al. 2014).
DCs are an immune cell population that is highly susceptible to AhR activation by
an array of ligands and are present in most tissues. Considering the important role of DCs
in thymocyte selection and the numerous, broad effects of AhR activation in DCs, the
consequences of AhR activation on DCs in thymus and their potential role in AhRinduced thymic atrophy is of key interest.
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SPECIFIC AIMS

AHR-MEDIATED THYMIC ATROPHY
Within the thymus, AhR activation by TCDD results in a dramatic loss of
developing thymocytes, which is associated with reduced frequency of double positive
(DP, CD4+CD8+) thymocytes, and relative increases in the frequency of double negative
(DN, CD4-CD8-) and single positive (CD4+ SP and CD8+ SP) thymocytes (Kamath et al.
1998; Kamath et al. 1997; Lundberg et al. 1990). Multiple mechanisms may contribute
to the loss of thymocytes, including reduced proliferation of DN precursor thymocytes
(Lai et al. 1994), enhanced apoptosis via Fas:FasL interactions at the DP stage (Camacho
et al. 2005b), and more rapid emigration of thymocytes to the periphery (Temchura et al.
2005). It is of keen interest to determine whether these effects are due to AhR activation
within the developing thymocytes and/or in other thymic cell populations of the thymus.
Studies using murine bone marrow chimeras showed that thymic atrophy by TCDD is
dependent on AhR activation within the hematopoietic compartment (Staples et al. 1998);
however, the hematopoietic compartment is highly heterogeneous, and the specific
immune cell contributor(s) have not yet been identified. Preliminary data from our
laboratory suggest that AhR activation in CD11c+ cells, a lineage marker for DCs, plays
a requisite role in TCDD-induced thymic atrophy. To corroborate these initial findings, it
is necessary to evaluate the role of AhR expression in other key lineages of the
hematopoietic compartment.
Additionally, while TCDD is the prototypical AhR ligand due to its demonstrated
high binding affinity, the AhR is a highly promiscuous receptor known to bind an array
of compounds (Pohjanvirta 2011). Dietary compounds such as indole-3-carbinol (I3C)
and endogenous compounds such as 2-(1H-Indol-3-ylcarbonyl)-4-thiazolecarboxylic acid
methyl ester (ITE) can bind and activate the AhR, and ligand-specific effects are known
to occur (Pohjanvirta 2011; Song et al. 2002). Of late, there has been substantial interest
in harnessing AhR-mediated immunosuppression for treatment of inflammatory diseases
(Quintana et al. 2010a); however, TCDD is highly toxic and natural AhR ligands are
gaining traction as promising alternatives. Therefore, it is also of great interest and
relevance to assess thymic atrophy in response to AhR ligands beyond TCDD. Thus, the
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first aim of this dissertation was to evaluate thymic atrophy by a select panel of ligands
and determine the role of AhR activation within hematopoietic cell lineages for TCDDmediated thymic atrophy.

AGONIST-LOADED LIPOSOMAL NANOPARTICLES FOR THERAPEUTIC
ACTIVATION OF THE AHR.
AhR activation is a potent immune-modulator and shows immense promise in the
treatment of autoimmune diseases (Quintana et al. 2010a). However, it is well
documented that the effects of AhR activation during an immune response vary based on
the target cell (Esser and Rannug 2015; Kreitinger et al. 2016; Stockinger et al. 2014) and
that AhR activation can result in drastically different outcomes, from increasing
inflammatory responses to promoting immune regulation or tolerance (Lee et al. 2015b).
Harnessing the immunosuppressive effects of AhR activation within specific immune cell
populations through a targeted delivery system would enable treatment of immune and
inflammatory diseases while circumventing the deleterious effects of systemic AhR
activation and subsequent non-specific immune modulation. Specifically, DCs
constitutively express AhR at high levels, are keenly sensitive to AhR expression by
multiple ligands, and adopt a regulatory phenotype that directly induces Tregs, making
them an attractive target for AhR agonists (Quintana et al. 2010c; Simones and Shepherd
2011).
While AhR activation in DCs holds immense promise for treatment of
autoimmune and inflammatory diseases, TCDD is highly toxic and exhibits a long halflife in humans; properties that make TCDD undesirable for pharmaceutical use (Harris et
al. 1973; Kerkvliet 2012; Miniero et al. 2001). Natural AhR ligands, such as ITE, are
more desirable for therapeutic purposes; however, natural ligands are more rapidly
metabolized than TCDD and thus require higher and more frequent doses (Abron et al.
2018; Benson and Shepherd 2011b; Song et al. 2002). Importantly, packaging
compounds within nanoparticles has been shown to improve drug solubility and potency,
reduce off-target effects, and protect the drugs against metabolic degradation
(Akbarzadeh et al. 2013). Liposomal nanoparticles (LNPs) are biodegradable and
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biocompatible delivery systems for enhanced therapeutic benefits, both in vitro and in
vivo, and are considered to be the most successful drug-carrier system to date (Bozzuto
and Molinari 2015). Taken together, it is of keen interest to develop ITE-loaded LNPs
and to evaluate ITE-loaded LNPs for biological effects in dendritic cells. Thus, the
second aim of this dissertation was to generate ITE-loaded LNP, to assess LNP uptake
efficiency, cytotoxicity, and phenotypic changes in bone marrow derived dendritic cells in
vitro, and to evaluate biodistribution of LNPs in vivo.

Specific Aim 1: Evaluate thymic atrophy by a select panel of ligands and determine
the requirement of AhR activation within hematopoietic cell lineages for TCDDmediated thymic atrophy.
Hypothesis: AhR activation induces thymic atrophy in a ligand-dependent
manner and AhR expression within CD11c+ DCs is necessary for thymic atrophy
by TCDD.
Specific Aim 2: Generate ITE-loaded LNP, assess LNP uptake efficiency,
cytotoxicity, and phenotypic changes in bone marrow derived dendritic cells
(BMDCs) in vitro, and evaluate biodistribution of LNP in vivo.
Hypothesis: We hypothesize that delivery of AhR agonist-loaded liposomal
nanoparticles will activate the AhR leading to a BMDC phenotype similar to
TCDD, and result in cell-specific uptake in vivo.
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Abstract
In nearly every species examined, administration of the persistent environmental
pollutant, 2,3,7,8-tetrachlorodibenzo-p-dioxin (dioxin, TCDD) causes profound immune
suppression and thymic atrophy in an aryl hydrocarbon receptor (AhR)-dependent
manner. Moreover, TCDD alters the development and differentiation of thymocytes,
resulting in decreases in the relative proportion and absolute number of double positive
(DP, CD4+CD8+) thymocytes, as well as an enrichment in the relative proportion and
absolute number of double negative (DN, CD4-CD8-) and single positive (SP) CD4+CD8and CD4-CD8+ thymocytes. Previous studies suggested that the target for TCDD-induced
thymic atrophy resides within the hematopoietic compartment and implicated apoptosis,
proliferation arrest of thymic progenitors, and emigration of DN thymocytes to the
periphery as potential contributors to TCDD-induced thymic atrophy. However, the
precise cellular and molecular mechanisms involved remain largely unknown.

Our

results show that administration of 10 g/kg TCDD and 8 mg/kg 2-(1H-Indol-3ylcarbonyl)-4-thiazolecarboxylic acid methyl ester (ITE) induced AhR-dependent thymic
atrophy in mice on day 7 following exposure, whereas 100 mg/kg indole 3-carbinol (I3C)
did not. Though our studies demonstrate that TCDD triggers a 2-fold increase in the
frequency of apoptotic thymocytes, TCDD-induced thymic atrophy is not dependent on
Fas-FasL interactions and thus, enhanced apoptosis is unlikely to be a major mechanistic
contributor. Finally, our results show that activation of the AhR in CD11c + dendritic cells
is directly responsible for TCDD-induced alterations in the development and
differentiation of thymocytes, which results in thymic atrophy. Collectively, these results
suggest that CD11c+ dendritic cells play a critical role in mediating TCDD-induced
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thymic atrophy and disruption of T lymphocyte development and differentiation in the
thymus.
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Introduction

The thymus is a complex, specialized organ that is responsible for the maturation
and education of most peripheral T cells. Progenitor cells enter the thymus from the
blood stream after originating in the bone marrow and/or fetal liver. Once in the thymus,
these cells progress through multiple developmental stages that can be delineated by cell
surface markers such as CD3, CD4, and CD8. In the earliest stage, classified as double
negative (DN) thymocytes, cells do not express any of these markers. Subsequently, cell
surface markers are up-regulated to give rise to CD4+CD8+ double positive (DP) cells,
which then undergo a rigorous selection process eventually down-regulating either CD4
or CD8 expression to become CD4+ or CD8+ single-positive (SP) cells, which are
released into the periphery. Self-reactive cells failing negative selection are removed via
apoptotic pathways, and mature, self-tolerant SP thymocytes are released into the
periphery as naïve Th cells (CD4) or cytotoxic T cells (CD8). Because ongoing
thymopoiesis is essential for the development and maintenance of a healthy immune
system, agents that trigger thymic atrophy may decrease host ability to reconstitute the
peripheral T cell repertoire or respond to new antigens. Similarly, because the overall
process of maturation and education of T cells is orchestrated, to a degree, by the
supporting cells of the stromal network, which includes thymic epithelial cells, dendritic
cells, and macrophages (Nowell et al. 2007), agents that induce thymic atrophy may be
acting on a variety of cellular targets.
The aryl hydrocarbon receptor (AhR) is a ligand activated transcription factor
belonging to the Per-ARNT-SIM-basic-helix-loop-helix (PAS/bHLH) protein family,
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which mediates a wide range of biological responses resulting from exposures to both
natural and synthetic ligands (Gu et al. 2000; Okey 2007; Pohjanvirta 2011). AhR was
first identified in the early 1970s and has since been shown to have dual roles as an
activator of xenobiotic metabolism and as a participant in normal homeostasis,
organogenesis, and immune modulation (Nebert and Gelboin 1968; Nebert and Gelboin
1969; Okey 2007; Wright et al. 2017). Nevertheless, details of the cellular and molecular
mechanisms underlying many AhR-dependent physiological and toxicological effects are
currently unknown.
Halogenated dioxins, biphenyls, and polycyclic aromatic hydrocarbons represent
the best-characterized high-affinity, planar, and hydrophobic ligands of the AhR.
Although numerous high affinity AhR ligands have since been discovered, the potent and
persistent environmental pollutant, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD, dioxin)
remains the prototypic AhR ligand for mechanistic studies (Kerkvliet 2012; Poland et al.
1976). Exposure of laboratory rodents to TCDD and TCDD-like chemicals profoundly
affects the immune system, causing immunosuppression typified by suppressed cellular
immunity, inhibition of antibody production, and thymic atrophy in a variety of animal
species (Faith and Luster 1979; Funatake et al. 2005; Harris et al. 1973; Kerkvliet 2002;
Poland and Glover 1980; Van Loveren et al. 1991; Vecchi et al. 1980) via direct effects
of AhR activation (Fernandez-Salguero et al. 1996; Harrill et al. 2016; Staples et al.
1998). C57Bl/6 mice, which harbor the AhRb allele that codes for a receptor with a high
binding affinity for agonists, exhibit a decrease in thymic weight and cellularity as early
as three days after exposure to a single 30 g/kg dose of TCDD (Laiosa et al. 2003a).
Maximal decline in thymocyte cellularity emerges 10 days later, yet recovery to near
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baseline levels does not occur until approximately 30 days after exposure (Laiosa et al.
2003a).
During TCDD-induced thymic atrophy, the thymus undergoes a marked reduction
in the frequency of DP thymocytes, as well as a relative increase in the frequency of DN
and SP thymocytes. Moreover, based upon the observed values for thymic cellularity,
these shifts in thymocyte subset frequencies correspond to significant decreases in the
absolute number of thymocytes in each of the four subpopulations (Kamath et al. 1998;
Kamath et al. 1997; Lundberg et al. 1990). Although the precise cellular and molecular
mechanisms involved remain largely unknown, previous studies demonstrated that the
target for TCDD-induced thymic atrophy resides within the hematopoietic compartment
and implicated reduced proliferation of DN precursor thymocytes (Lai et al. 1994),
enhanced apoptosis via Fas:FasL interactions at the DP stage (Camacho et al. 2005b), and
enhanced emigration of thymocytes (Temchura et al. 2005), or a combination of these
possible mechanisms. Therefore, it was of great interest to evaluate TCDD-induced
thymic atrophy in naïve wild-type mice (C57Bl/6), mice expressing the low affinity AhR
(AhRd), and AhR conditional knockout mice (LyzMCreAhRfx, CD11cCreAhRfx,
RORcCreAhRfx, and FoxN1CreAhRfx). Furthermore, we assessed whether an endogenous,
non-toxic AhR ligand 2-(1H-Indol-3-ylcarbonyl)-4-thiazolecarboxylic acid methyl ester
(ITE) (Abron et al. 2018; Benson and Shepherd 2011b; Song et al. 2002) and a dietary
AhR ligand, indole 3-carbinol (I3C) (Benson and Shepherd 2011b; Bjeldanes et al. 1991;
Connor and Finley 2003) exhibited thymotoxic effects similar to TCDD. The findings
presented here extend our understanding of how activation of the AhR contributes to
thymic atrophy and mediates immune suppression.

42

Materials and Methods
Chemicals
2,3,7,8, tetrachlorodibenzo-p-dioxin (dioxin, TCDD) was obtained from
Cambridge Isotopes (Cambridge, MA). A 1 mg/mL stock solution of TCDD in
anisole/peanut oil was diluted to yield treatment solutions containing 1 or 10 μg/mL in
peanut oil. 2-(1H-Indol-3-ylcarbonyl)-4-thiazolecarboxylic acid methyl ester (ITE) was
obtained from Tocris (Bio-techne brand, Minneapolis, MN). A 20 mg/mL stock solution
of ITE in DMSO was diluted to yield a treatment solution containing 0.8 mg/mL in
peanut oil. Indole 3-carbinol (I3C), obtained from Sigma-Aldrich (St. Louis, MO), was
suspended in peanut oil (10 mg/mL). The estimated half-life of TCDD is approximately
10 days in mice (Birnbaum 1986; Gasiewicz et al. 1983), whereas the in vivo absorption,
metabolism, distribution, and excretion rates of ITE and I3C in mice remain largely
undetermined. Therefore, we selected the dose and route of exposure based upon earlier
reports, thus integrating our results with previous findings in other model systems (Abron
et al. 2018; Benson and Shepherd 2011a; Boule et al. 2018b; Nugent et al. 2013;
Quintana et al. 2010c; Singh et al. 2016).

Biohazard precaution
TCDD is highly toxic and a known human carcinogen. All personnel were
instructed in safe handling procedures. Proper personal protective equipment (e.g. lab
coats, gloves and masks) were worn at all times, and contaminated materials were
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collected separately for hazardous waste disposal. TCDD-treated mice were housed
separately, and their carcasses and bedding regarded as contaminated materials.

Mice
Breeding pairs of mice were originally purchased from The Jackson Laboratory
(Bar Harbor, ME) and maintained as both individual colonies and crossed strains to yield
AhR conditional knockouts (supplemental Table 1). Tails snips were digested in direct
PCR lysis reagent according to the manufacturer’s protocol (Viagen Biotech, Los
Angeles, CA). Mice of the correct genotype were identified according to PCR conditions
furnished by the Jackson Laboratory, and littermates were used as controls. All mice
were maintained in microisolator cages in the University of Montana specific pathogenfree (SPF) laboratory animal facility, and provided breeder (Teklad 2019, Envigo,
Denver, CO) or standard rodent chow (Teklad 2020x, Envigo) and tap water ad libitum.
All animal use procedures were in accordance with NIH and University of Montana
IACUC guidelines.

In Vivo Exposure
Naïve, adult (6-10-week-old) mice received 10 or 100 μg TCDD/kg, 1 to 8 mg/kg
ITE, or 100 mg/kg I3C (Camacho et al. 2005b; Nguyen and Bradfield 2007; Quintana et
al. 2010a; Singh et al. 2014) via oral gavage (p.o.) or intraperitoneal injection (i.p.) as
described in the appropriate results sections. Control mice received solvent/peanut oil or
a peanut oil only vehicle control. Each experiment was performed in duplicate or
triplicate with age-matched littermates (+7 days), containing a minimum of three mice of
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each sex for n=6 per treatment group. Mice were weighed daily, tissues collected 7 days
later, and analyzed individually.

Cell Isolation
Following euthanasia by CO2 asphyxiation, body weights were recorded and
thymi removed free of lymph nodes and blood vessels. Individual thymi were weighed
and pressed through a 70 m sterile cell strainer with the flat end of a 1 mL syringe
plunger to release the cells into cold complete RPMI (cRPMI) media supplemented with
10% FBS (Atlanta Biologicals, Atlanta, GA), 50 M β-mercaptoethanol, 20 mM 4-(2hydroxyethyl)-1-piperazineethanesulfonic acid, 10 mM sodium pyruvate, and 50 g/ml
gentamicin (Gibco, Grand Island, NY) (Corning, Manassas, VA). Thymocytes were
pelleted by centrifugation at 1500 rpm for 5 minutes, re-suspended in fresh cRPMI, and
maintained on ice.

Flow cytometry
Single cell suspensions of thymocytes were washed once with cRPMI and resuspended in 100 μl of purified rat anti-mouse CD16/CD32 (2.4G2, Tonbo, San Diego,
CA) diluted 1:100 in PBS containing 1% bovine serum albumin and 0.1% sodium azide
(PAB) to block Fc receptors. 2 x 106 thymocytes were immunostained for 30 minutes on
ice with titrated monoclonal antibodies specific to CD3 PerCPCy5.5 (145-2C11,
Tonbo), CD4 FITC or redfluor 710 (RM4-5, Tonbo), and CD8 PE-Cy7 (53-6.7, Tonbo)
to identify live, propidium iodide (PI, Tonbo) negative singlet thymocytes. Another 2 x
106 thymocytes were immunostained for 30 minutes on ice with monoclonal antibodies
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specific to CD45 v450 (30-F11, Tonbo), CD4 FITC (RM4-5, Tonbo), CD8α PE-Cy7 (536.7, Tonbo), CD11c PE (HL3, BD Pharmingen, San Diego, CA), Fas Alexa Fluor 647
(Jo2, BD Pharmingen), FasL PerCP Cy5.5 (MFL3, BD Pharmingen) to identify cell
surface expression of Fas and FasL.

Alternatively, 2 x 106 thymocytes were

immunostained with monoclonal antibodies specific to CD4 FITC (RM4-5, Tonbo),
CD8α PE-Cy7 (53-6.7, Tonbo), in addition to Annexin V and 7-AAD staining solution
according to the manufacturer’s instructions (Tonbo). Unstained, single stained, and
fluorescence minus one controls were used to set positive/negative gating. Cells were
washed twice with 1 mL PAB and re-suspended in 350 L of PAB and acquisition was
performed on a FACS Aria II flow cytometer using FACS Diva software (v 6.1.2, Becton
Dickinson, Franklin Lakes, NJ). Compensation of the spectral overlap was performed
using One Comp compensation control beads (BD Biosciences, San Diego, CA) in
combination with single stained controls where appropriate. Data files were exported as
FCS 3.1 files and analyzed by Flow Logic (v 4.0, Miltenyi, Auburn,CA).

RNA isolation and RT-qPCR
Total RNA was extracted from 5 x 106 thymocytes using TRIzol reagents
(Invitrogen) or a RNeasy mini kit (Qiagen, Germantown, MD) according to the
manufacturer protocols. Two-step qRT-PCR was performed by synthesizing cDNA using
iScript Reverse Transcription Supermix (BioRad, Hercules, CA) followed by RT-qPCR
relative quantification of 50 ng cDNA per reaction using CFX Connect, SSO Advanced
Universal SYBR Green Master Mix, and PrimePCR validated primers for murine
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GAPDH, Hprt, Tbp, Fas, and FasL (BioRad, Hercules, CA). The data were normalized to
the reference genes Hprt, Tbp, and GAPDH.

Statistical Analysis
For each parameter, the values for individual experiments were averaged and the
standard error calculated. Student t-tests, one-way or two-way ANOVA were performed
using Prism 7 (GraphPad, La Jolla, CA). A p value of ≤ 0.05 was considered significant.

Results
ITE, but not I3C, induces thymic atrophy
Although AhR activation promotes immunoregulatory responses in a liganddependent manner (Ehrlich et al. 2018), little is known about the thymotoxic effects of
other AhR ligand chemotypes. To test the hypothesis that activation of the AhR induces
thymic atrophy in a ligand-dependent manner, C57Bl/6 mice were gavaged with an
endogenous ligand (ITE) (Song et al. 2002) and a dietary ligand (I3C) (Connor and
Finley 2003), with chemical structures that are distinct from TCDD (Figure 1A). The
dose and route of exposure to each chemical were selected based on prior reports, thus
simplifying integration of our results with previous findings (Benson et al. 2012b; Boule
et al. 2018b; Quintana et al. 2010b). After daily administration of 8 mg/kg ITE, C57Bl/6
mice exhibited extensive thymic atrophy as evidenced by a significant loss in organ
weight (52% decrease) and a dramatic reduction in thymic cellularity (73% decrease)
relative to vehicle control on day 7. In contrast, administration of 100 mg/kg I3C to
C57Bl/6 mice every other day resulted in a trend towards increased thymic weight and a
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significant increase in cellularity (30% increase) relative to vehicle control on day 7
(Figure 1B and 1C). No sex-specific effects were observed at day 7 with ITE or I3C
(data not shown). Because ITE and I3C differentially affected thymic weight and
cellularity, we also compared effects on intra-thymic differentiation by assessing the
surface expression of CD4 and CD8 on live thymocytes via flow cytometry (Figure 2).
Although administration of ITE revealed a trend similar to TCDD with regards to a
significant reduction in the frequency of DP and increase in the frequency of DN and
CD4+ SP thymocytes, no difference was observed in the frequency of CD8+ SP
thymocytes compared to vehicle control. Lastly, administration of I3C to C57Bl/6 mice
resulted in no significant changes in the development and/or differentiation of any
CD4/CD8 thymocyte subsets examined (Figure 2.1 and Figure 2.2). Together, these data
show that activation of the AhR induces thymic atrophy in a ligand-dependent manner.

48

Figure 2. 1 ITE, but not I3C, induces thymic atrophy.
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Figure 2.1 ITE, but not I3C, induces thymic atrophy.
Naïve wild-type mice (C57Bl/6) were gavaged with 3 chemically distinct AhR
ligands (A): TCDD (10 µg/kg), ITE (8 mg/kg), or I3C (100 mg/kg). Three
indicators of toxicity: body weight (data not shown), thymus weight (B), and
thymus cell numbers (C) were measured on day 7 to evaluate toxicity and thymic
atrophy after administration of TCDD, ITE, and I3C. Data represent one of two
independent experiments, n=3-5 per treatment group, mean + SEM; 1-way
ANOVA, *p < 0.05 vehicle.
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Figure 2. 2 Comparison of CD4/CD8 thymocyte subsets from vehicle, TCDD, ITE, and I3C
exposed mice
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Figure 2. Comparison of CD4/CD8 thymocyte subsets from vehicle, TCDD, ITE,
and I3C exposed mice.
C57Bl/6 mice were gavaged with the appropriate vehicle control, TCDD (10 µg/kg,
once), ITE (8 mg/kg daily), or I3C (100 mg/kg every other day). Representative
contour plots gating on live thymocytes revealed a significant decline in the
frequency of CD4+CD8+ DP thymocytes, as well as a relative enrichment in the
percent of CD4-CD8- DN and CD4+CD8- and CD4-CD8+ SP thymocytes in 10 g/kg
TCDD- and 8 mg/kg ITE-treated mice compared to vehicle controls on day 7. These
shifts in CD4/CD8 thymocyte subsets were not observed in mice treated with 100
mg/kg I3C. The mean percentages of the CD4/CD8 thymocyte subsets + SEM are
indicated in the plots. Data represent one of two independent experiments, n=3-5 per
treatment group; 1-way ANOVA, *p < 0.05 vehicle.
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ITE induces thymic atrophy in a dose- and AhR-dependent manner
Although exposure to ITE in vitro caused dose-dependent alterations in
thymocyte differentiation and maturation that paralleled those observed following in vitro
exposure to TCDD, previous reports did not detect changes in thymus weight 12 days
following a single delivery of 5.6 mg/kg ITE (i.v.) (Henry et al. 2006). To test the
hypothesis that ITE induces thymic atrophy in an AhR-dependent manner, C57Bl/6 and
low affinity AhRd mice were gavaged daily with a previously described
immunosuppressive dose of ITE (Abron et al. 2018; Henry et al. 2006; Nugent et al.
2013; Quintana et al. 2010b) and tissues analyzed at day 7. First, we confirmed that mice
expressing the low affinity AhRd allele do not exhibit thymic atrophy when exposed to 10
g/kg TCDD and that a 10-fold higher dose of TCDD (e.g. 100 g/kg) in AhRd mice
overcame the low-affinity receptor, resulting in thymic atrophy (Supp. Figure 2.1 and
2.2). This supplemental data support the use of AhR d mice as a model to evaluate ligands
for AhR-dependent effects. ITE exposure to naive C57Bl/6 mice resulted in thymic
atrophy as evidenced by a significant decline in organ weight (49% decrease) and a
reduction in thymic cellularity (73% decrease) relative to vehicle control. In contrast,
AhRd mice were refractory to the same 8 mg/kg dose of ITE with regards to thymic
weight (Figure 2.3A) and cellularity (Figure 2.3B). Likewise, the dose-dependent effects
of ITE were scrutinized in C57Bl/6 mice by assessing thymic weight and cellularity.
Daily administration of 1, 2, 4, and 8 mg/kg ITE (p.o.) resulted in dose-dependent thymic
atrophy as evidenced by a decline in organ weight of 13%, 25%, 30% and 35%,
respectively (Figure 2.3C) and a dramatic decrease in thymic cellularity of 25%, 25%,
40% and 50% (Figure 2.3D) respectively, in C57Bl/6 mice relative to vehicle control on
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day 7.

Lastly, comparable levels of thymic atrophy were observed following daily

administration of 1 mg/kg ITE i.p. and 4 mg/kg ITE p.o. (data not shown).

Figure 2. 3 ITE-induced thymic atrophy in an AhR- and dose-dependent manner.
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Figure 2.3. ITE-induced thymic atrophy in an AhR- and dose-dependent manner.
Naïve wild-type mice (C57Bl/6) and mice expressing the low affinity receptor (AhR d
mice) were gavaged with vehicle (anisole/peanut oil) or ITE (8 mg/kg). Three indicators
of toxicity: body weight (data not shown), thymus weight (A), and thymus cell number
(B) were measured on day 7 to evaluate toxicity and thymic atrophy. n=5-6 mice per
treatment group, mean + SEM; 1-way ANOVA, *p < 0.05 vehicle. An additional cohort
of C57Bl/6 mice were gavaged with vehicle (anisole/peanut oil) or increasing doses of
ITE (1, 2, 4, or 8 mg/kg). Three indicators of toxicity: body weight (data not shown),
thymus weight (C), and thymus cell number (D) were measured on day 7 to evaluate
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toxicity and thymic atrophy. n=5-6 mice per treatment group, mean + SEM; 1-way
ANOVA, *p < 0.05 vehicle.
Dioxin-mediated thymic atrophy is not dependent on apoptosis via Fas:FasL interactions
Since TCDD has been reported to initiate apoptosis in immature thymocytes
(Fisher et al. 2004; Rhile et al. 1996) and Fas:FasL interactions have been implicated in
this process (Dencker et al. 1985; Kamath et al. 1999a), C57Bl/6 mice were treated with
10 g/kg TCDD and the degree of apoptosis measured by assessing the expression of
7AAD and Annexin V, as well as Fas and FasL on thymocytes via flow cytometry.
Representative dot plots gating on singlet thymocytes revealed a slight, but statistically
significant increase in the frequency of Annexin V+7AAD- apoptotic thymocytes in 10
g/kg TCDD-treated mice (6.5% + 0.8 of thymocytes) compared to vehicle (3.8% + 0.6
of thymocytes) on day 7 (Figure 2.4A). However, this did not correspond to a significant
increase in the absolute number of apoptotic cells—perhaps due to the massive decline in
thymus cellularity (data not shown). Moreover, representative dot plots gating on
Annexin V+7AAD- apoptotic thymocytes revealed that the majority of apoptotic cells
were DP thymocytes, followed by DN and CD4+ SP thymocytes, with very few apoptotic
cells observed in the CD8+ SP subset. In contrast, TCDD exposed animals exhibited a
distribution shift at day 7—resulting in an increased frequency of Annexin V +7AADapoptotic thymocytes within the DN, CD4+, and CD8+ SP thymocytes and a decreased
frequency of Annexin V+7AAD- apoptotic thymocytes being of the DP thymocyte subset
(Figure 2.4A and 2.4B). Additionally, C57Bl/6 mice were treated with 10 g/kg TCDD
and Fas-FasL gene expression was analyzed in freshly isolated thymocytes on days 3, 7,
and 14 post exposure. TCDD resulted in no change in either Fas or FasL gene expression
as measured by quantitative RT-PCR (data not shown).

Furthermore, 3 days after
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administration of TCDD to C57Bl/6 mice, there were no observable effects on the
frequency nor the MFI of Fas and FasL expression on live CD45 + thymocytes relative to
vehicle controls (Figure 2.5a). Because previous studies reported that dioxin induced
FasL-dependent thymocyte cell death (Camacho et al. 2005a; Kamath et al. 1999b), we
examined the role of Fas-FasL signaling in TCDD-induced thymic atrophy using FasLdeficient (gld/gld) mice. FasL deficient mice were exposed to 10 g/kg TCDD (p.o.) and
their thymic weight and cellularity measured on day 7. Contrary to a previous report
(Kamath et al. 1999b), FasL-deficient mice in our experiments were not protected against
TCDD-induced thymic atrophy and exhibited significant reductions in thymic weight
(60% decrease) and cellularity (70% decrease) comparable to wild-type C57Bl/6 mice
(Figure 2.5B). Similarly, representative dot plots (gating on live thymocytes) revealed a
significant decline in the frequency of DP thymocytes, as well as a relative enrichment in
the percent of DN and CD4+ and CD8+ SP thymocytes in 10 g/kg TCDD-treated mice
compared to vehicle control (Figure 2.5C).
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Figure 2. 4 The effect of TCDD on apoptotic thymocytes.
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Figure 2.4. The effect of TCDD on apoptotic thymocytes.
Naïve wild-type mice (C57Bl/6) were gavaged with vehicle (anisole/peanut oil) or
TCDD (10 g/kg). Representative contour plots gating on 7-AAD+Annexin V+
thymocytes revealed a significant increase in the frequency of apoptotic thymocytes (A),
as well as a dramatic shift in the distribution of thymocytes which were undergoing
apoptosis 7 days following exposure to TCDD (B). Data represent one of two
independent experiments, n=3-5 mice per treatment group, mean + SEM; 1-way
ANOVA, *p < 0.05 vehicle.
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Figure 2. 5 TCDD-mediated thymic atrophy is not dependent on Fas-FasL interactions
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Figure 2.5. TCDD-mediated thymic atrophy is not dependent on Fas-FasL
interactions. Naïve wild-type mice (C57Bl/6) were gavaged with vehicle
(anisole/peanut oil) or TCDD (10 g/kg). Representative contour plots gating on
singlet thymocytes revealed that 3 days after administration of vehicle or 10 g/kg
TCDD to C57Bl/6 mice, there were no observable effects on the frequency of Fas and
FasL expression on CD45+ thymocytes relative to vehicle control (A). FasL deficient
(gld/gld) mice were exposed to 10 g/kg TCDD and their thymic weight and
cellularity measured on day 7 (B). Similarly, representative dot plots (gating on live
thymocytes) revealed a significant decline in the frequency of DP thymocytes, as well
as a relative enrichment in the percent of DN and CD4 +CD8- and CD4-CD8+ SP
thymocytes in 10 g/kg TCDD-treated FasL deficient (gld/gld) mice compared to
vehicle control (C). n=5 mice per treatment group, mean + SEM; t-test, *p < 0.05 56
vehicle.

Targeted deletion of the AhR in CD11c+ dendritic cells protects against dioxin-induced
thymic atrophy
Previous studies revealed that the target/s for TCDD-induced thymic atrophy
reside within the hematopoietic cells and not stromal tissues (Staples et al. 1998);
however, it is uncertain which hematopoietically derived cells contribute to TCDDinduced thymic atrophy. To determine how AhR signaling in specific immune cells
mediates TCDD-induced thymic atrophy, we generated AhR conditional knockout mice
for myeloid derived cells (LyzMCreAhRfx), CD11c+ dendritic cells (CD11cCreAhRfx),
RORt+ DP and SP thymocytes (RORcCreAhRfx), and thymic epithelial cells
(FoxN1CreAhRfx). Mice were dosed with solvent/peanut oil vehicle or 100 g/kg
TCDD—a dose of dioxin necessary to elicit thymotoxic endpoints in conditional AhR fx/fx
mice which carry the low affinity AhRd allele (Poland and Glover 1980; Walisser et al.
2005). Seven days later, Cre-AhRfx/fx and AhRd mice, as well as LyzMCreAhRfx,
RORcCreAhRfx, and FoxN1CreAhRfx exhibited extensive thymic atrophy as evidenced by a
decline in organ weight (68%, 63%, and 63% decrease, respectively) (Figure 2.6A) and a
dramatic reduction in thymic cellularity (89%, 89%, and 82% decrease, respectively)
(Figure 2.6B) relative to vehicle control. In contrast, CD11c CreAhRfx mice were protected
from TCDD-induced thymic atrophy and showed no significant difference from vehicle
controls in either thymic weight (Figure 2.6A) or cellularity (Figure 2.6B).

These

findings led us to further investigate whether targeted deletion of the AhR in specific
immune cell types also facilitates TCDD-induced effects on intra-thymic development
and differentiation. Representative dot plots from AhR d, LyzMCreAhRfx, RORcCreAhRfx,
and FoxN1CreAhRfx mice administered 100 g/kg TCDD echoed the typical alterations in
thymocyte subsets which can be observed in wild-type mice following exposure to
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TCDD: decreases in the frequency of DP thymocytes and increases in the frequency of
DN, CD4+, and CD8+ SP thymocytes compared to vehicle control (data not shown).
Importantly, representative dot plots gating on live thymocytes from CD11c CreAhRfx
mice treated with 100 g/kg TCDD exhibited protection from TCDD-induced alterations
in thymocyte subsets (Figure 2.7). Because conditional Cre negative x AhR fx/fx mice carry
the low affinity AhRd allele (Poland and Glover 1980; Walisser et al. 2005), this strain
can be utilized interchangeably with Cre-AhRfx as controls for experiments involving
AhR conditional knockout mice (supplemental Figure 2.3). Collectively these data show
that targeted deletion of the AhR in CD11c+ dendritic cells protects against TCDDinduced thymic atrophy.
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Figure 2. 6 Deletion of the AhR in CD11c+ dendritic cells protects against dioxininduced thymic atrophy.

A.
thymus weight (mg)

80
60
40
20
0

*

*

AhR d Cre-AhR fx CD11c

*

*

*

LyzM

RORc

FoxN1

AhR conditional knockout

thymus cellularity (x 106)

B.
vehicle
TCDD

100
80
60

*

40
20
0

*
AhRd Cre-AhRfx CD11c

*

*

*

LyzM

RORc

FoxN1

AhR conditional knockout

Figure 2.6. Deletion of the AhR in CD11c+ dendritic cells protects against dioxininduced thymic atrophy.
AhR conditional knockout mice were generated for myeloid derived cells
(LyzMCreAhRfx), CD11c+ dendritic cells (CD11cCreAhRfx), RORt+ DP and SP
thymocytes (RORcCreAhRfx), and thymic epithelial cells (FoxN1CreAhRfx). Mice were
exposed to either solvent/peanut oil vehicle or 100 g/kg TCDD. Three indicators of
toxicity: body weight (data not shown), thymus weight (A), and thymus cell number
(B) were measured on day 7. Data represent one of three independent experiments,
n=3-4 mice per treatment group, mean + SEM; 2-way ANOVA, *p < 0.05 vehicle.
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Figure 2. 7 Comparison of CD4/CD8 thymocyte subsets from CD11cCreAhRfx and AhRd mice
exposed to vehicle or TCDD.
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Figure 2.7. Comparison of CD4/CD8 thymocyte subsets from CD11cCreAhRfx and
AhRd mice exposed to vehicle or TCDD.
AhR conditional knockout and AhRd control mice were exposed to either
solvent/peanut oil vehicle or 100 g/kg TCDD. Representative contour plots gating on
live thymocytes revealed a significant decline in the frequency of CD4 +CD8+ DP
thymocytes, as well as a relative enrichment in the percent of CD4-CD8- DN and
CD4+CD8- and CD4-CD8+ SP thymocytes in AhRd mice exposed to 100 g/kg TCDD
compared to vehicle controls on day 7. These shifts in CD4/CD8 thymocyte subsets
were not observed in CD11cCreAhRfx mice treated with TCDD. The mean percentages
of the CD4/CD8 thymocyte subsets + SEM are indicated in the plots. Data represent
one of three independent experiments, n=3-4 per treatment group; 2-way ANOVA, *p
< 0.05 vehicle.
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Discussion

Administration of dioxin (TCDD) and dioxin-like chemicals to laboratory rodents
dramatically affects the immune system, triggering immunosuppression characterized by
suppressed cellular immunity, inhibition of antibody production, and thymic atrophy
(Silkworth and Antrim 1985; Silkworth et al. 1986)—effects which are dependent on the
AhR (Fernandez-Salguero et al. 1996; Harrill et al. 2016; Staples et al. 1998). Unlike
many nuclear receptors, the AhR is a highly promiscuous receptor, directly binding a
wide variety of structurally diverse natural and synthetic compounds, thereby promoting
the up- or down-regulation of a multitude of target genes in different tissues. The
spectrum of biological effects produced by the ligand/AhR/ARNT signaling complex is
dependent on the physicochemical characteristics and persistence of the ligand (Ehrlich et
al. 2018). To date, most analyses exploring AhR-induced immune modulation have
taken advantage of TCDD’s specificity and high affinity for the AhR (6 pM – 2.4 nM), as
well as its long half-life (~11 days in mice; 8-10 years in humans) (Miniero et al. 2001).
However, the same properties that make TCDD an excellent tool also contribute to its
profound toxicity. While other ligands such as ITE and indole-3-carbinol (I3C) can
activate the AhR and have been evaluated as potential therapeutics (Abron et al. 2018;
Quintana et al. 2010c; Yeste et al. 2012), little is known about their potential thymotoxic
effects. Thus, the present study investigated the effects of an endogenous (ITE) and a
dietary (I3C) ligand on thymic development and differentiation.
Administration of 8 mg/kg ITE to C57Bl/6 mice resulted in a dramatic reduction
in organ weight and thymic cellularity on day 7. In contrast, administration of 100 mg/kg
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I3C to C57Bl/6 mice resulted in a slight increase in thymic weight and a significant
increase in cellularity. Because previous studies in a murine colitis model suggested that
sex-specific effects existed with select AhR ligands (Benson et al. 2012a), we also tested
the hypothesis that male vs. female mice would exhibit disparate thymic atrophy
following activation of the AhR. Interestingly, no sex specific effects were observed
with regards to thymic weight or cellularity following exposure to TCDD, ITE, or I3C.
Likewise, because AhR activation by TCDD and TCDD-like compounds results in
alterations in the frequency of thymocyte subsets, we investigated whether ITE and I3C
similarly affected thymic development and differentiation. Our results demonstrate for
the first time that ITE induced thymic atrophy, as well as reduced the frequency of DP
thymocytes and increased the frequency of DN, CD4+ and CD8+ SP thymocytes—albeit
to a slightly lesser degree than TCDD. These data are in contrast to a previous report
(Henry et al. 2006), which did not detect changes in thymus weight 12 days following a
single delivery of 5.6 mg/kg ITE (i.v.). It is likely that the discrepancy between our
results and the study by Henry et al., 2006 reside in the differences between dose (acute
vs sub-acute) and route of delivery (i.v. vs. p.o.) of the AhR ligand (Boule et al. 2018b;
Ehrlich et al. 2018). Interestingly, I3C did not result in thymic atrophy with a slight
increase in thymic cellularity being observed. This divergence in effects between two
natural AhR ligands was surprising as the administered doses had both been shown to
elicit immunosuppressive effects, and the thymus is known to be acutely sensitive to AhR
ligands. Importantly, the previously reported immunosuppression observed with I3C
occurred within the intestines, which given the oral route of administration as well as
documented non-enzymatic cleavage of I3C into additional AhR ligands by gastric acid,
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it is conceivable that higher concentrations of I3C and its newly formed metabolites are
available within the gut (Benson et al. 2012a; Bjeldanes et al. 1991; Perdew et al. 2015).
Recent advances in AhR biology further suggest that binding affinity and ligand
metabolism may be better predictors of immunosuppressive outcome than ligand source
(Boule et al. 2018a). Therefore, further analysis of I3C through a higher dose response as
well as administration of purified metabolites would better evaluate I3C for effects on the
thymus. Together, this is the first study to compare AhR activation by different types of
compounds on thymocyte development and differentiation; thus, extending our
knowledge of ligand-specific, AhR-mediated immunotoxic effects.
Because we observed gross thymic atrophy with ITE, we more extensively
characterized the ability of ITE to induce thymic atrophy.

Following previously

published dosing regimens (Nugent et al. 2013; Quintana et al. 2010b), our data clearly
demonstrate that daily administration of 8mg/kg ITE p.o. induced significant thymic
atrophy in an AhR-dependent manner. In addition, ITE induced noticeable decreases in
both thymic weight and cellularity at doses as low as 1 mg/kg. Moreover, 4m/kg ITE p.o.
and 1mg/kg i.p. induced comparable levels of thymic atrophy in C57Bl/6 mice,
demonstrating that ITE causes thymic atrophy regardless of the route of systemic
exposure. This point is particularly important given the growing interest in AhR research
on identifying novel classes of potent, non-toxic AhR ligands for use in various
therapeutic settings (Stockinger 2009). Moreover, these observations raise concerns about
potential off-target immune toxicities associated with the use of ITE based immune
therapies (Abron et al. 2018; Dolciami et al. 2018; Hao and Whitelaw 2013; Nugent et al.
2013; Quintana et al. 2010c).
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Multiple mechanisms for TCDD induced thymic hypocellularity have been
suggested including reduced proliferation of DN precursor thymocytes (Lai et al. 1994),
enhanced apoptosis at the DP stage (Camacho et al. 2005b), and enhanced emigration of
thymocytes (Poland et al. 1994; Temchura et al. 2005), or a combination of these possible
mechanisms. Apoptosis occurs normally during development and aging as a homeostatic
mechanism to maintain cell populations in tissues, and as a defense mechanism when
disease or noxious agents damage cells. Although apoptosis was reported to underlie
TCDD-induced thymic atrophy (Kamath et al. 1998; Kamath et al. 1997), and thymic and
peripheral T cells are highly sensitive to TCDD-induced apoptosis in vitro (Camacho et
al. 2004), our work and that of others (Comment et al. 1992; De Heer et al. 1994;
Silverstone et al. 1994a; Silverstone et al. 1994b; Staples et al. 1998) have failed to
support this in vivo. In the current study, we investigated whether 10 g/kg TCDD
initiates apoptosis in C57Bl/6 mice by quantifying the frequency and absolute number of
apoptotic thymocytes by flow cytometry on day 7 post-exposure. Although TCDDinduced thymic atrophy corresponded with an almost doubling of the frequency of
Annexin V+7-AAD- apoptotic thymocytes compared to control animals, this did not
correspond to a significant increase in the absolute number of apoptotic cells—likely due
to the massive decline in overall thymus cellularity observed with exposure to TCDD.
Earlier studies suggested that the timing and pathway of apoptosis was important to AhRmediated thymic atrophy (Kamath et al. 1998) and implied Fas-FasL interactions
regulated apoptosis during TCDD-induced thymic atrophy (Camacho et al. 2005a). This
led us to assess the mRNA expression of Fas and FasL using qRT-PCR on days 3, 7 and
14 after administration of 10 g/kg TCDD in naïve wild-type C57Bl/6 mice, which did
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not support TCDD-mediated induction of Fas and/or FasL gene expression in the thymus.
Analysis of Fas and FasL protein expression by flow cytometry 3 days after
administration of 10 g/kg TCDD to C57Bl/6 mice, further confirmed these results at the
protein level.
Because apoptotic cells may be rapidly cleared by phagocytic cells in vivo (Platt
et al. 1998), we also probed the role of Fas-FasL interactions in TCDD-induced thymic
atrophy using FasL-deficient (gld/gld) mice. In our studies, FasL-deficient (gld/gld) mice
exposed to 10 g/kg TCDD experienced the same degree of thymic atrophy as Fas-FasL
competent control mice and thymocyte subsets demonstrated no protection from TCDDinduced alterations. Interestingly, assessment of an apoptosis and survival RT-PCR array
yielded four genes which showed a significant increase in expression: BAD (7-fold
change vs vehicle), Akt1 (4-fold change vs vehicle), and Pik3cd (2.5-fold change vs
vehicle), Ppp3ca (2.5-fold change vs vehicle) in thymocytes on day 7 and no genes which
were significantly reduced in expression. These data are consistent with evidence that
suggests that apoptosis and survival genes in thymocytes are in constant flux.
Collectively, our results fail to support Fas-FasL-mediated apoptosis as a mechanism of
TCDD-induced thymic atrophy. These findings are in direct contrast to previously
published reports, which implicated Fas-FasL interactions as playing an important role in
TCDD-mediated induction of apoptosis and immunotoxicity (Camacho et al. 2002;
Kamath et al. 1999b; Rhile et al. 1996). In a majority of the previously reported in vivo
studies, C57Bl/6 mice were exposed to 30-50 g/kg TCDD intraperitoneally (i.p.), and
evaluated shortly thereafter, 6-24hrs, whereas in our study C57Bl/6 mice were exposed to
10 ug/kg TCDD through oral gavage (p.o) and evaluated 3-14 days post-exposure.
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Pharmacokinetics indicate that TCDD is more readily metabolized following p.o. than
i.p. administration (Olson et al. 1980), thus we would expect that p.o. administration
would yield lower bioavailability than i.p. delivery. These differences in dose and
administration route may yield a substantially lower systemic TCDD concentration in our
studies, and thus leads us to question whether exceedingly high concentrations of
systemic TCDD initiate an immediate apoptotic response that does not last beyond the
early time points tested by Camacho et al. (2005a). Supporting this, it was initially
reported that thymocytes exhibit markers of apoptosis up until 24-hours post exposure
(Camacho et al. 2005a); however, maximal thymic atrophy does not occur until 7-10 days
post-exposure in adult mice (Silverstone et al. 1994a). Together, this may explain the
difference in reports and suggests that apoptosis may be the most immediate, although
not the most substantial mechanism, involved in thymic atrophy following exposure to
lower concentrations of TCDD.
Previous studies identified the AhR signaling pathway as the pivotal event in
TCDD-induced thymic atrophy (Laiosa et al. 2003b; Staples et al. 1998) and the
hematopoietic compartment as the target for TCDD-induced thymic atrophy (Staples et
al. 1998). However, until now, it was unclear which hematopoietically derived cell/s
triggered TCDD-induced thymic atrophy. To investigate the importance of cell-specific
AhR signaling in TCDD-induced thymic atrophy, mice expressing the AhR floxed allele
(AhRfx) were crossed to mice expressing Cre transgenes driven by LyzM (myeloid
derived cells), CD11c (dendritic cells), RORt (DP and SP thymocytes), and FoxN1
(thymic epithelial cells) specific promoters. Our results show for the first time that
deletion of the AhR in CD11c+ dendritic cells prevents TCDD-induced thymic atrophy, a
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previously unreported phenomenon. Therefore, the immunotoxic responses of TCDD on
the thymus are dependent on AhR activation in CD11c+ dendritic cells. DCs make up a
small percentage of the thymic stroma (Wu and Shortman 2005) and are located mainly
in the medulla and corticomedullary region. Thymic DCs cross-present self-antigens to
developing thymocytes, facilitate the generation of regulatory T cells, and act as
gatekeepers of lymphocyte trafficking (Bonasio et al. 2006; Hubert et al. 2011; Lei et al.
2011; Proietto et al. 2008b). DCs are thus poised to exert control over thymic output in
response to environmental conditions. Unfortunately, the solubility limitations of ITE
(~30 mg/mL DMSO) and I3C (~10 mg/mL in ethanol) prevent the use of either of these
ligands in AhR conditional knockout mice at doses that would be expected to induce
thymic atrophy. Together, the current study significantly advances our understanding of
how the AhR regulates immune responses and demonstrates for the first time that TCDDinduced thymic atrophy occurs as a result of activation of the AhR in CD11c + dendritic
cells. Identification of CD11c+ dendritic cells as the direct target of TCDD-induced
thymic atrophy offers insights into novel pathways to further understand the mechanisms
of AhR-mediated immune regulation. Collectively, this work emphasizes the importance
of research examining the contribution of cell- and tissue-specific consequences of
chemical exposures on immune responses.
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Chapter 2 Supplemental Figures
Table 2. 1 Supplemental Mouse strains examined in this study
Strain
C57BL/6J

Common Stock #
name
C57BL/6 000664

B6.D2N-Ahrd/J

AhRd

002921

B6Smn.C3-Faslgld/J

Gld

0010210

B6.129P2Lyz2tm1(cre)Ifo/J

LyzMCre

004781

B6.Cg-Tg(Itgaxcre)1-1Reiz/J

CD11cCre

008068

B6(Cg)Foxn1Cre
Foxn1tm3(cre)Nrm/J

018448

B6.FVB-Tg(Rorccre)1Litt/J

RORtCre

022791

Ahrtm3.1Bra/J

AhRflox

006203

Relevant Phenotype(s)
Express the AhRb allele and are
sensitive to TCDD-induced toxicity at
10 µg/kg
Express the AhRd allele and are
sensitive to TCDD-induced toxicity at
100 µg/kg
Unable to express functional Fas
Ligand
Allow for targeted deletion of the AhR
in cells of the myeloid lineage:
monocytes, mature macrophages, and
granulocytes
Allow for targeted deletion of the AhR
in cells of the dendritic lineage:
conventional and plasmacytoid
dendritic cells
Allow for targeted deletion of the AhR
in thymic epithelial cells and
keratinocytes.
Allow for targeted deletion of the AhR
in DP thymocytes and their SP
progeny.
Use to generate cell/tissue-specific
mutants of the aryl-hydrocarbon
receptor (AhR)

Figure 2. 8 Supplemental Figure 1. AhRd mice are unresponsive to TCDD-induced thymic
atrophy at 10 g/kg.
vehicle
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Supplemental Figure 1. AhRd mice are unresponsive to TCDD-induced thymic atrophy at 10
g/kg. Naïve wild-type mice (C57Bl/6) and mice expressing the low affinity receptor (AhR d
mice) were gavaged with vehicle (anisole/peanut oil) or TCDD (10 or 100 µg/kg). Three
indicators of toxicity: body weight (data not shown), thymus weight (A), and thymus cell number
(B) were measured on day 7 to evaluate toxicity and thymic atrophy after low dose (10 g/kg)
and high dose (100 g/kg) of TCDD. Data represent one of two independent experiments, n=4-6
per treatment group, mean + SEM; 2-way ANOVA, *p < 0.05 vehicle.

Figure 2. 9 Supplemental Figure 2. Comparison of CD4/CD8 thymocyte subsets from vehicle
and TCDD-exposed mice.
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Supplemental Figure 2. Comparison of CD4/CD8 thymocyte subsets from vehicle and
TCDD-exposed mice. C57Bl/6 and AhRd mice were gavaged with vehicle (anisole/peanut
oil) or TCDD (10 or 100 µg/kg). Representative contour plots gating on live thymocytes
from wild-type C57Bl/6 mice revealed a significant decline in the frequency of CD4 +CD8+ DP
thymocytes, as well as a relative enrichment in the percent of CD4-CD8- DN and CD4+CD8and CD4-CD8+ SP thymocytes in 10 g/kg TCDD-treated mice compared to vehicle control
on day 7. These shifts in CD4/CD8 thymocyte subsets were not observed in AhR d mice
treated with 10 g/kg TCDD but were observed following administration of 100 g/kg
TCDD. The mean percentages of the CD4/CD8 thymocyte subsets + SEM are indicated in the
plots. Data represent one of two independent experiments, n=4-6 per treatment group; 2way ANOVA, *p < 0.05 vehicle
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Abstract
The AhR is a critical regulator of both innate and adaptive immune responses
with potent immunomodulatory effects that make the AhR an attractive molecular target
for novel therapeutics. Harnessing the immunosuppressive effects of AhR activation
holds immense promise; however, the prototypical AhR ligand 2,3,78,8 tetracholoro-pdioxin, is highly toxic and not compatible for use in humans. Natural AhR ligands offer a
safer alternative to TCDD, but barriers exist due to their rapid degradation, poor
solubility, and high-dosing schemes. Packaging AhR agonists in liposomal nanoparticles,
a biodegradable and biocompatible drug delivery system, offers an intriguing solution.
Here, the thin film hydration method was used to develop Cy5-labelled PEGylated
liposomal nanoparticles (LNP) loaded with the natural AhR ligand, 2-(1′H-indole-3′carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE). ITE entrapment efficiency was
>90%, and LNP demonstrated long-term chemical and physical stability. LNP enabled
steady release of ITE under physiological parameters with minimal drug escape or burst
effect being observed. Murine bone marrow derived dendritic cells (BMDCs) cultured
with LNP exhibit >85% cellular interaction efficiency with LNPs as measured by
fluorescent cytometry and laser scanning cytometry. LNP exposure does not reduce cell
viability in vitro, and ITE-loaded LNP induce AhR responsive genes, including CYP1a1,
TGFβ3, and IDO1/2. Furthermore, LNP administered intraperitoneally accumulated in
the spleen with highest uptake occurring by splenic APCs. Collectively, these results
demonstrate LNP delivery of AhR agonists as a promising mechanism for targeted, cellspecific AhR activation.
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Introduction
The Aryl hydrocarbon Receptor (AhR) is a potent immune-modulator and
promising target for the treatment of autoimmune diseases, allergies, and chronic
inflammatory disorders (Kerkvliet et al. 2009; Quintana et al. 2010a; Zhang et al. 2010).
AhR activation by the high affinity ligand, 2,3,7,8 tetrachlorodibenzo-p-dioxin (TCDD),
results in pronounced immune suppression through the induction of suppressive immune
cells including regulatory T cells (Tregs) and tolerogenic dendritic cells (DCs) (REF).
However, TCDD is a highly toxic and persistent compound, which effectively eliminates
its therapeutic use in humans (Needham et al. 1999). Numerous natural compounds
generated endogenously and derived from plants, such as 2-(1H-Indol-3-ylcarbonyl)-4thiazolecarboxylic acid methyl ester (ITE), indirubin-3’-oxime (IO), and indole-3carbinol (I3C) can activate the AhR and can promote tolerogenic DCs and Tregs,
providing favorable alternatives to TCDD for therapeutic AhR activation (Abron et al.
2018; Benson et al. 2012a; Benson and Shepherd 2011b; Boule et al. 2018a; Ehrlich et al.
2018; Singh et al. 2014). However, as AhR activation and natural agonists gain traction
for pharmaceutical use, solutions are needed to overcome current barriers that reduce
efficacy and practicality of natural ligands including poor solubility, rapid metabolism in
vivo, and the requirement of frequent administration of high doses.
Numerous nanoparticle formulations are gaining traction as drug delivery
systems. Liposomal nanoparticles (LNPs) are optimal biodegradable and biocompatible
delivery systems to enhance therapeutic benefits, both in vitro and in vivo, and are
considered to be the most successful drug-carrier system to date (Bozzuto and Molinari
2015; Kraft et al. 2014). LNPs have been shown to improve drug solubility and potency,
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reduce off-target effects, protect drugs against metabolic degradation, and enable
controlled drug release, which together, result in an increased therapeutic index
(Akbarzadeh et al. 2013; Singh et al. 2014). Therefore, development of an ITE-loaded
LNP could mitigate current obstacles associated with natural AhR agonist-based
therapies and enable sustained, concentrated drug delivery to target tissues, while
reducing adverse outcomes of systemic exposure and off-target effects.
Within the immune system, AhR expression varies significantly by cell type,
maturation state, and activation status (Kreitinger et al. 2016). It is well documented that
the effects of AhR activation during an immune response vary based on the target cell
(Esser and Rannug 2015; Kreitinger et al. 2016; Stockinger et al. 2014) and that AhR
activation can result in drastically different outcomes, from increasing inflammatory
responses to promoting immune regulation or tolerance (Lee et al. 2015b). DCs,
professional antigen-presenting cells that bridge the innate and adaptive immune system,
constitutively express AhR at high levels and are keenly sensitive to AhR activation by
multiple ligands (Bankoti et al. 2010a; Bankoti et al. 2010b; Kreitinger et al. 2016). AhR
activation within DCs has been shown to induce a potent regulatory phenotype that
promotes peripheral immune tolerance via induction of indoleamine-2,3-dioxygenase
(IDO) and transforming growth factor beta (TGFβ) isoforms, and generation of Tregs
(Mezrich et al. 2010; Nguyen and Bradfield 2007; Simones and Shepherd 2011; Vogel et
al. 2008). Together, DCs are an attractive focus for delivery of concentrated AhR
agonists (Quintana et al. 2010c; Simones and Shepherd 2011).
In the present study, we aimed to develop fluorescently labeled, PEGylated ITEloaded LNPs using the thin film hydration method for delivery to dendritic cells. LNPs
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were characterized for average particle size, long-term physical and chemical stability,
and ITE entrapment efficiency. LNP uptake and drug delivery were evaluated in vitro
through cultures with bone marrow derived dendritic cells (BMDCs), and in vivo
biodistribution was assessed within lymphoid tissues following intraperitoneal
administration. Together, the results from this study support PEGylated LNPs as an
effective ITE delivery system.

Materials and Methods
Chemicals
1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE), 1,2-distearoyl-snglycero-3-phosphocholine

(DSPC),

and

1,2-distearoyl-sn-glycero-3-

phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt) (DSPEmPEG2000) were purchased from Avanti Polar Lipids, Inc (Alabaster, AL, USA).
Cyanine5 NHS ester (Cy5) was obtained from Lumiprobe Corp., Hallandale Beach, FL,
USA). Cholesterol, chloroform (CHCl3), methanol (MeOH), triethylamine HPLC grade,
and ethyl ether anhydrous ACS grade were purchased from Fisher scientific (Pittsburgh,
PA, USA). 0.1M Phosphate Buffered Saline (PBS) pH 7.4, was purchased from EMD
Millipore (Billerica, MA, USA). 2-(1H-Indol-3-ylcarbonyl)-4-thiazolecarboxylic acid
methyl ester (ITE) was purchased from Tocris (St Louis, MO, USA). Thin-layer
chromatographic analyses were performed on Sigma-Aldrich 60 F254 thin-layer
chromatographic plates. Column chromatography was performed with silica gel 230-400
mesh. 1H NMR spectra were recorded on a Bruker Avance IIITM spectrometer at 400MHz
and are reported in parts per million (ppm) on the δ scale relative to tetramethylsilane as
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an internal standard. 13C NMR spectra were recorded at 100 or 125 MHz and are reported
in parts per million (ppm) on the δ scale relative to CDCl 3.Signals were abbreviated as
follows: s = singlet, br s = broad singlet, d = doublet, t = triplet, q =quadruplet, m =
multiplet. Coupling constants (J) are expressed in hertz. All solvents and chemicals used
were reagent or analytical grade when not specified, and used as received.

Procedure for the Preparation of Cy5-labelled DPPE
A previously published procedure was adapted to synthesize Cy5-NHS (Mizrahy
et al. 2014). Cy5-NHS (12 mg, 0.019 mmol) was dissolved in 2 ml of DMF and 1 ml of
CHCl3. Then, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE) (13.2 mg,
0.019 mmol) was added followed by the addition of Et3N (2.6 µL, 0.019 mmol) (Figure
1). The reaction mixture was heated to 70°C and stirred overnight. Upon completion, the
solvent was removed under reduced pressure and the crude product was purified by
column chromatography (length 15.5 cm; diameter 15 cm) on silica gel (gradient 100,
5:95, 10:90, 15:85 MeOH:DCM) to afford the Cy5–DPPE conjugate as a blue solid. Mass
spectrometry spectra were obtained on a Waters/Micromass LCT-TOF instrument in
methanol: M + H)+ 1156, purity>95%. 1H NMR (400 MHz, CDCl3/CD3OD: 2/1) δ 8.13
(s, 1H), 8.06 – 7.86 (m, 1H), 7.43 (d, J = 7.2 Hz, 1H), 7.35 – 7.13 (m, 3H), 6.64 (t, J
=12.5 Hz, 1H), 6.23 (dd, J = 18.4, 13.8 Hz, 2H), 5.37 (s, 1H), 5.24 (s, 1H), 4.43 (d, J =
11.9 Hz, 1H), 4.20 (dd, J = 12.0, 6.7 Hz, 1H), 4.14 – 3.90 (m, 8H), 3.62 (s, 3H), 3.44 (s,
4H), 2.42 – 2.23 (m, 4H), 1.83 (d, J = 6.8 Hz, 2H), 1.74 (s, 8H), 1.52 (d, J = 7.3 Hz, 2H),
1.26 (s,48H), 0.88 (t, J = 6.1 Hz, 6H). Rf of Cy5-DPPE: 0.6 in 10/90
methanol:dichloromethane.
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Figure 3. 1 Preparation of Cy5-labelled DPPE

Figure 3.1 Preparation of Cy5-labelled DPPE
Schematic of fluorescent molecule, Cy5-NHS, added to 1,2-dipalmitoyl-sn-glycero-3phosphoethanolamine (DPPE) for incorporation into, and tracking of, liposomal
nanoparticles.

Preparation of Liposomal nanoparticles (LNPs) by lipid film hydration
The lipid mixture (0.85 mM) composed of DSPC: cholesterol: DSPE-mPEG2000:
Cy5-DPPE at a molar ratio of 59:34:5:2 was dissolved in a chloroform:methanol mixture
(2:1, vol/vol) in a round bottom flask. 1 µM ITE stock solution in DMSO was added to
the lipid mixture and the resulting solution was dried to a thin and transparent film using
a rotary evaporator (Buchi Rotavapor R-215, Switzerland) under reduced pressure
(Bangham et al. 1974). Multilamellar vesicles (MLVs) were obtained by hydration of the
film with PBS (pH 7.4). After five cycles of freezing and thawing, the liposome diameter
was reduced by ultrasonication with a probe sonicator (MISONIX Microson™r XL2000,
Farmingdale, NY, USA) and samples filtered through PFTE syringe filter, 0.2 µm, to
remove the titanium fragments. ITE-loaded liposomal nanoparticles (ITE-LNPs), nonfluorescent and fluorescent empty liposomal nanoparticles were prepared following the
steps described above. All the LNPs were stored at 4°C prior to analysis and experiments.
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MLVs lyophilization and rehydration
The MLVs were prepared as above. Polysorbate 20 (5% of total lipids weight) or
trehalose (4:1 lipids ratio) was added to the MLVs suspension and stirred at 65°C
immediately after the freezing and thawing cycles. The MLVs suspension was frozen at 80°C and then lyophilized using a Labconco Dry Ice Benchtop Freeze Drying System
(Kansas City, MO, USA). The resulting powder was stored at 4°C and rehydrated at
different time points with PBS (pH 7.4) to its original volume. The liposome diameter
was reduced by ultrasonication with a probe sonicator (MISONIX Microson™r XL2000,
Farmingdale, NY, USA) and filtered through PFTE syringe filter, 0.2 µm, to remove the
titanium fragment. The SUVs were stored at 4°C prior to analysis.

Morphological studies
Transmission electron microscopy (TEM) and scanning electron microscopy (SEM)
were used to characterize the surface and structure of ITE-loaded LNP samples,
respectively. Samples prepared for TEM were placed on single slot formvar-coated 400
mesh copper grids. Excess sample was blotted off with filter paper, and the grid was then
stained with 1% phosphotungstic acid solution for 1 minute. Stain was blotted dry from
the grids with filter paper and air-dried. Samples were imaged with a Hitachi H-7100
TEM (Hitachi, Tarrytown, NY, USA) at 75kV. ITE-loaded LNP samples prepared for
SEM were placed on a 0.1 um pore PVDF filter and allowed to air dry. Dried LNP
samples were placed on a non-conductive carbon adhesive tape applied on aluminum stub
and coated with gold using a Denton Desk V sputter coater (Denton Vacuum LLV,
Moorestown, NJ). Samples were imaged using a Hitachi S-4700 Field Emission scanning
electron microscope
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Size distribution and surface potential measurements
Mean diameter, size- distribution, polydispersity index (PDI) and zeta potential of
the LNPs were determined at 25°C by dynamic light scattering (DLS) using a Zetasizer
nano ZS (Malvern Intruments Ltd, Malvern, UK). Samples were analyzed 24H after
preparation and three measurements were taken on each sample.

Determination of ITE entrapment efficiency
The entrapment efficiency for ITE was determined using a Waters HPLC Alliance
system on an e2695 separations module with a Waters 2998 photo-diode array (PDA)
detector (Milford, MA, USA). Samples were injected using a Waters auto injector and the
instrument was controlled by use of MassLynx™ software (Milford, MA, USA).
Components were separated on a Waters Phenomenex ™ C18 reversed-phase column
(Milford, MA, USA) with 50 x 4.6 mm dimensions and 3 μm particle size. The column
was kept thermostatic at 30°C in a Waters column oven (Milford, MA, USA). HPLC
baseline resolution was obtained by employing a gradient elution at a flow rate of 0.3
ml/min with a gradient mobile phase composed of methanol (0.1% formic acid) (B) and
water (0.1% formic acid)(A) ramped over a 12 minute period using the following
conditions: and monitored at 360 nm as follows: The binary linear gradient began from a
mixture of 10% A and 90% B and ended at 2% A and 98% B at 6.60min. After the 1.40
min. plateau at 2% A and 98% B, the mobile phase composition changed back to its
initial composition starting at 8 min. in 4 min. The ITE entrapment efﬁciency in LNPs
was expressed as entrapment percentage (EE%) and calculated through the following
relationship: EE% = (Ctotal – Cfree)/ Ctotal] X 100. The free drug (Cfree) was separated by
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pressure ultrafiltration method using an Amicon 8010 (Millipore Corporation, bedford,
USA) at 50psi and determined by the LC/MS method described above. The total content
of ITE (Ctotal )in the suspensions was determined after the ITE-loaded LNPs suspensions
were frozen at -80°C and then lyophilized using a Labconco Dry Ice Benchtop Freeze
Drying System (Kansas City, MO, USA). The ITE-loaded LNP powders were then
diluted with methanol to disrupt the LNPs, release the entrapped drug into the solvent and
to afford the LC/MS injectate solution. Peaks of products were monitored using the
LC/MS method described above. The concentrations of ITE were determined using a
calibration curve of the pure drugs in methanol solutions at the wavelength where it
showed maximum absorbance (360 nm). The area under the curve was converted into
percentage using a standard curve, and experiments were performed in triplicate in order
to ensure accuracy.

Stability study of ITE-loaded LNPs
The stability of the ITE-loaded LNPs in suspension and lyophilized form was
evaluated initially and after storage at +4°C for three months. The particle size
distribution, the polydispersity index and the total drug content of the samples were
determined as a function of the storage time.

In vitro release kinetics
ITE release from LNPs was studied using a dialysis method. Dialysis cassettes
(Slide-A-Lyzer Dialysis Cassettes 10K MWCO, Thermo Fisher Scientific, Waltham,
MA, USA) were immersed before use in ultrapure water overnight at 4°C to remove the
preservative, followed by rinsing in PBS (pH 7.4) solution. 1 mL of ITE-loaded LNPs
suspension (0.3μg ITE) was injected into the dialysis cassette and dialyzed at 37°C
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against 100 mL of PBS (pH 7.4). The sink conditions may permit the free ITE released
from the LNPs to migrate through the dialysis membrane without precipitating as the
solubility of ITE has been calculated to be 0.05mg/mL (ChemAxon Aqueous Solubility
Predictor - Version 16.3.14.0) in PBS (pH 7.4). At various time points (0-120H), 20 mL
aliquots of the release buffer were withdrawn for analysis and replaced by 20 mL of fresh
release medium. The samples were lyophilized and stored at 4°C until analysis. The
amount of drug released was quantified using the LC/MS method described above. Drug
release profile from LNPs was expressed as release percentage (RP%) and calculated
through the following relationship: %RP= [Creleasel / Ctotal] X 100. Where Crelease is the
amount of ITE released at a specific time and Ctotal is the total amount of ITE in LNPs.

Thermal analysis
DSC analysis of the lyophilized empty and ITE-loaded LNPs was performed
using a TA instruments Q10 model (TA Instruments, New Castle, DE, USA). Calibration
of the instrument was done using Indium for the best heat capacity at constant pressure
(Cp) estimate and high signal-to-noise ratio. Two mg of lyophilized LNPs samples were
loaded in hermetically sealed aluminum pans along with the standard reference aluminum
in the differential scanning calorimeter. The DSC was recorded between 10°C and 90°C
at a scan rate of 1°C/min for three cycles and the last reproducible heating cycle was
considered for analysis.

Mice
C57Bl/6 mice were originally obtained from The Jackson Laboratories (Bar
Harbor, ME) and were bred and maintained in the animal research facilities at the
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University of Montana. Mice were housed under specific pathogen-free conditions and
maintained on 12 h dark/light cycles. Standard laboratory food and water were provided
ad libitum. All protocols for the use of animals were approved by the University of
Montana Institutional Animal Care and Use Committee and adhered to the current
National Institutes of Health (NIH) guidelines for animal usage.
Bone Marrow Derived Dendritic Cell (BMDC) Cultures
Cellular uptake assays were performed using Bone Marrow Derived Dendritic
Cells (BMDCs). BMDCs were generated from 7-day cultures of bone marrow-derived
progenitor cells from femurs and tibias of C57Bl/6 mice (Bankoti et al., 2010). Briefly,
hematopoietic progenitor cells were collected by flushing murine femurs and tibias with
complete RMPI media (cRPMI) (Gibco, Grand Island, NY) supplemented with 10% fetal
bovine serum (Atlanta Biologicals, Atlanta, GA), 50µM 2-mercaptoethanol, 20mM 4-(2hydroxyethyl)-1-piperazineethanesulfonic acid, 10mM sodium pyruvate, and 50 µg/ml
gentamicin (Gibco, Grand Island, NY) (Corning, Manassas, VA). Red blood cells were
removed through density gradient centrifugation using Lympholyte-M reagent (Cedarlane
Laboratories Limited, Ontario, Canada). Isolated hematopoietic precursors were then
cultured at a density of 1x106 cells/ml in T75 tissue culture flasks for 7 days at 37°C and
5% CO2 in the presence of 30 ng/ml murine granulocyte macrophage-colony stimulating
factor (GM-CSF) (PeproTech, Rocky Hill, NJ). cRPMI and GM-CSF growth factor were
refreshed on days 3 and 5. On day 7, nonadherent cells were harvested and BMDC purity
was verified via fluorescence cytometry. BMDCs were then re-cultured in 6-well plates
with LNPs at 10-1,10-2,10-3 to yield ITE-loaded LNP concentrations [100nM, 10nM, 1nM
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respectively] for 24-96 hours or with 10nM 2,3,7,8, tetrachlorodibenzo-p-dioxin (dioxin,
TCDD) in DMSO (Cambridge, MA).
Dye exclusion viability assays
To assess effects of LNP uptake on cell viability, cultured cells were treated with
optimum titrations of propidium iodide (PI) nucleic acid stain (Sigma-Aldrich) as a
membrane exclusion assay via fluorescence cytometry. As a control for dead or dying
cells, 1x106 BMDCs were incubated at 55°C for >10-minutes and then stained with PI as
described above.

In vivo LNP exposure
Naïve, adult (8-14 week-old) C57Bl/6 mice received 10uL LNP/gram body
weight or PBS control via intraperitoneal injection (i.p.) daily for three consecutive days.
Mice were weighed daily and tissues were collected 24 hours after the last injection.
Following CO2 euthanasia, blood was collected through cardiac puncture in EDTA (0.5
M) coated syringes. Tissues were collected and processed through 70μM cell strainers in
cRPMI and maintained on ice prior to downstream assays.
Fluorescence cytometry
Fluorescence cytometry to assess cellular uptake of Cy5-labeled LNPs was
performed using a FACS Aria II flow cytometer (v 6.1.2, Becton Dickinson, Franklin Lakes,
NJ) or Attune NxT Acoustic Focusing Flow Cytometer (Thermo Fisher Scientific,

Waltham, MA). Cells were harvested and washed with PAB (1% bovine serum albumin
and 0.1% sodium azide in PBS), followed by a 10-minute incubation with anti-
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CD16/CD32 Fc Block (BioLegend, San Diego, CA) to eliminate non-specific staining
(Shepherd et al., 2001). Antibodies used in these experiments included CD11c-PE (HL3
and N418), F4/80-BV421 (BM8), CD11b-PE-Dazzle594 (M1/70), CD3-Percp/Cy5.5
(145-2C11), CD19-FITC (MB19-1), MHCII-FITC (M5/114.15.2), and CD86-BV510
(GL-1), and were obtained from Biolegend (San Diego, CA), Tonbo (San Diego, CA),
and BD Biosciences (San Jose, CA). All staining was performed at optimized titrations
for 20 minutes, on ice, and protected from light. To control for spectral spreading and
autofluorescence by the LNPs, control samples were treated with empty liposomes
lacking Cy5. Fluorescence Minus One (FMO) controls were used for gating controls.
BDCompBeads (BD Biosciences, San Jose, CA) compensation beads were used for
compensation controls.
Fluorescence microscopy
Laser scanning cytometry (LSC/iCys, CompuCyte, Cambridge, MA) was used to
corroborate cellular interaction with Cy5+ LNPs. Cells were adhered to glass slides using
the Cytospin 3 (Thermo Fisher Scientific, Waltham, MA) at a concentration of 1x10 5
cells/slide.

Cells were stained with diamidino-2-phenylindole (DAPI) nuclear stain

(Thermo Fisher Scientific, Waltham, MA) and treated with Prolong Gold Antifade
Mountant (Thermo Fisher Scientific, Waltham, MA) prior to cover slide placement. iCys
CompuCyte software (Cambridge, MA) was used for obtaining images and calculating
fluorescence intensity of samples. Cells exposed to unlabeled (Cy5-), empty LNPs were
used as controls for autofluorescence.
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RNA isolation and RT-qPCR
Total RNA was extracted from 5 x 106 BMDCs using a RNeasy mini kit (Qiagen,
Germantown, MD) according to the manufacturer protocols. Two-step RT-qPCR was
performed by synthesizing cDNA using iScript Reverse Transcription Supermix (BioRad,
Hercules, CA) followed by RT-qPCR relative quantification of 50 ng cDNA per reaction
using CFX Connect, SSO Advanced Universal SYBR Green Master Mix, and PrimePCR
validated primers for murine CYP1A1, IDO1, IDO2, TGFΒ3 (BioRad, Hercules, CA).
The data were normalized to the reference genes, GAPDH and HPRT, and displayed
relative to control.

Statistical analyses
Data sets with multiple comparisons were evaluated by one-way analysis of
variance (ANOVA) followed by post-hoc analysis using student’s t-test. Values of
p<0.05 were considered significant.

Results
LNPs are optimally sized, demonstrate high ITE entrapment efficiency, and maintain
long-term stability.
Nanocarrier size has been established as a crucial determinant for optimal cellular
delivery and should not exceed 500 nm (Olsen et al. 2011). Studies by Foged et al.
demonstrated that limiting NP size to 100 nm resulted in twice the cellular uptake
compared to larger NP (Foged et al. 2004); however, further reduction in size to 40nm
did not increase cellular uptake. Particle size analysis established that the average size of
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both freshly prepared and lyophilized PEGylated ITE-loaded LNPs was within the
optimal range, ~100 nm, with a unimodal size distribution, and a low polydispersity
index ≤0.2 (Figure 3.2a). The addition of Polysorbate 20 enabled median particle size of
lyophilized LNP to be comparable to fresh LNP through a shortened rehydration step (<
5min). To evaluate LNP morphology, SEM and TEM of ITE-loaded LNP were
performed. As modeled in Figure 3.2b, the ITE-loaded LNP should be composed of two
lipid layers with an aqueous core. Representative SEM and TEM images, shown in
Figure 3.2c and 3.2d, confirmed that ITE-loaded LNPs were spherical in shape,
maintained an aqueous core, and were in the same nanosize range as observed from DLS
measurements.
Previous studies have shown that high encapsulation efficiency of lipophilic drugs
and almost no drug loss can be achieved using the lipid film hydration method (Çağdaş et
al. 2014; Jesorka and Orwar 2008) ITE entrapment efficiency was greater than 70% for
freshly prepared and lyophilized PEGylated LNPs at both 1nM (data not shown) and
1µM ITE loading (Figure 3.3a). Compared to lyophilized LNPs, dramatically higher
entrapment efficiency was observed for the non-lyophilized LNPs, 72% and 94%
respectively. As expected, a reciprocal relationship occurred between LNP ITE loading
and free ITE concentrations with a higher level of free ITE detected in lyophilized LNP
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Figure 3. 2 Morphology and Characterization of ITE-loaded LNPs.

Figure 3.2 Morphology and Characterization of ITE-loaded LNPs.
Freshly prepared and lyophilized 1μM ITE-loaded PEGylated LNP were evaluated for
hydrodynamic diameter (nm), polydispersity, and z-Potential (mV) (A). LNP morphology
diagram depicting round morphology and ITE interaction with the lipid bilayer (B).
Representative images of morphology studies of ITE-loaded LNP through Transmission
Electron Microscopy micrograph (magnification X150000) (C) and Scanning Electron
Microscopy micrograph (magnification X150000) (D).
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(15.7%±2.1) compared to fresh LNP (2.2%±1.2); however, minimal ITE remained free in
either preparation. Together, these results confirm that freshly formulated and lyophilized
LNPs can be efficiently loaded with ITE and adopt an optimal size and morphology for
cellular uptake.
The effects of storage conditions on LNPs were evaluated because chemical and
physical stability over longer time periods is desirable for pharmaceutical applications.
Following synthesis, ITE-loaded LNPs were stored at 4°C for three months to assess
long-term chemical stability. As shown in Figure 3.3b, at 15 days and two months postsynthesis, there was no significant decrease in total drug loading in either fresh or
lyophilized LNP; however by three months a slight, statistically significant, decrease in
drug loading was observed in the lyophilized LNP (79%) compared to fresh LNP (85%).
Despite the slight decrease observed in total drug loading by month three, no degradation
product was identified, and stored LNPs elicited the same level of gene expression
(CYP1A1) as fresh LNP when tested in vitro (data not shown). Additionally, LNPs
showed high physical stability over three months whether stored at 4°C as an aqueous
colloidal suspension or rehydrated in PBS (pH 7.4) from the lyophilized cake. As shown
in Figure 3.3c, long-term storage did not significantly alter polydispersity of fresh LNP
(0.22 ± 0.02) or lyophilized LNP (0.15 ± 0.01) and mean diameters were equally
maintained in both fresh LNP (115.7nm ± 1.9) and lyophilized LNP (97.9nm ± 0.3).
Thus, both freshly prepared and lyophilized LNP demonstrate physical and chemical
stability over three months at 4°C.
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Figure 3. 3 Chemical and physical stability of ITE-loaded LNP

Figure 3.3 Chemical and physical stability of ITE-loaded LNP
Total ITE content and free ITE of LNP was determined using HPLC and calculated as EE%
= (Ctotal – Cfree)/ Ctotal] X 100 (A). Long term ITE entrapment was evaluated in LNP stored at
4°C for 15 days, 30 days, and 90 days prior to HPLC analysis (n=3) (B). Physical stability of
LNP was assessed for both fresh and lyophilized LNP at 90 days (C).
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ITE interacts with lipid bilayers of the LNP following drug loading and is released within
24-hours in vitro
ITE is a highly lipophilic compound due to its planar, aromatic structure, and
LNPs were observed to contain an aqueous core, together suggesting ITE containment is
occurring by the LNP lipid bilayer. To confirm this, differential scanning calorimetry
(DSC) thermograms of empty and ITE-loaded LNPs were performed. As shown in Figure
3.4, endothermic peaks of the phase transitions from a gel phase to a liquid crystalline
(Tm) phase were observed for both empty and ITE-loaded LNPs. The empty LNP
thermogram showed a broad endotherm at 34.09°C corresponding to lipid bilayer
components. The melting endotherm of the lipid bilayer components was found to be
shifted to 43.32°C, suggesting interaction of ITE with lipid bilayers (Hathout et al. 2007)
and successful drug encapsulation. In addition, enthalpy changes (δH cal) reflect the
differences in the packing properties of the acyl chains(Sade et al. 2010; Serro et al.
2014). As seen in Figure 3.4., δHcal increased from 0.06 J/g for the empty LNPs to 0.19
J/g for the ITE-loaded LNPs, which may indicate a more densly packed LNP membrane
following ITE loading.(Maswadeh et al. 2002; Sade et al. 2010).
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Figure 3. 4 Differential scanning calorimetry (DSC) thermograms of empty and
ITE-loaded LNPs

Figure 3.4 Differential scanning calorimetry (DSC) thermograms of empty and ITEloaded LNPs. The DSC was recorded between 10°C and 90°C at a scan rate of 1°C/min
for three cycles and the last reproducible heating cycle was considered for analysis.
Endorthermic peaks of empty LNP (solid) and ITE-loaded LNP (dashed) are shown.
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Previous studies have shown that uptake of nanoparticles in the size range of 100200 nm by dendritic cells can occur at a relatively fast rate, within 1 to 2 hours of in vitro
exposure at 37°C (Kochiadakis et al. 2001; Tacken et al. 2011; Tran et al. 2018). To
evaluate the rapidity of ITE release from LNPs in vitro, LNPs were incubated at 37°C
against 100-fold excess PBS (pH 7.4) under dialysis conditions for 120 hours (5 days)
and the cumulative percentage of ITE release was plotted versus time (Figure 3.5). A
sustained-release effect was observed for ITE as only 14% of the drug was released from
the LNPs in the first thirty minutes. The drug release profile fit a first kinetic order
release phase in the first 4 hours and then approached a plateau at 24 hours.
Approximately 50% of the total ITE dose was released within two hours in vitro and 90%
release observed by 24 hours. The plateau value represented ~95% release of total
incorporated drug and only ~3 % of the drug was still associated with the LNPs by day 5.
Thus, LNPs release ITE rapidly and completely in vitro.
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Figure 3. 5 In vitro ITE release curve from ITE-loaded LNPs under physiological
conditions.

Figure 3.5 In vitro ITE release curve from ITE-loaded LNPs under physiological conditions.
Dialysis of LNP at pH7.4 and 37°C to represent physiological conditions. Cumulative ITE
drug release was quantified by LC/MS over 100 hours where %= [Creleasel / Ctotal] X 100.
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Drug-loaded LNPs demonstrate increased uptake by BMDCs without affecting cell
viability.
Liposomal formulations are highly promising therapeutic delivery systems as
studies have demonstrated that LNPs are both biodegradable and biocompatible. To test
potential cytotoxicity of LNPs on target cells, murine BMDCs were generated and
exposed to three doses of empty LNP (ten-fold serial dilution of LNP:media 10 -1,10-2,103

) for 24 or 96 hours. BMDC LNP uptake efficiency was evaluated for dose and time-

dependent effects by measuring Cy5+ CD11c+ BMDCs via fluorescent cytometry. As
shown in Figure 3.6a, dose-dependent effects were observed at both time points as
BMDCs exposed to 10-1 LNP exhibited the highest frequency of Cy5+ (24H85.2%±0.78) compared to 10-2 LNP (24H-73%± 1.0) and 10-3 LNP (24H-44%±1.3).
LNP uptake occurred most rapidly and completely at high LNP concentrations with
greater time required for LNP uptake at lower concentrations. BMDCs were then stained
with propidium iodide (PI), a DNA intercalating agent that is unable to permeate healthy
cell membranes, for analysis of cell viability by fluorescence cytometry. As shown in
Figure 3.6b, compared to untreated cells, LNP exposure did not reduce BMDC viability
at any concentration following either 24-hour exposure (~86% viable) or 96-hour
exposure (~75% viable). Thus, LNPs interact with BMDCs rapidly and do not reduce cell
viability.
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Figure 3. 6 LNP interaction is dose and time dependent and does not reduce BMDC
viability.

Figure 3.6 LNP interaction is dose and time dependent and does not reduce BMDC viability.
Day 7 BMDCs were cultured with three concentration of LNP and interaction efficiency was
calculated as IE=[%LNP+CD11c+ cells/Total CD11c+ cells]x100 (A). Cell viability was evaluated
by propidium iodide nuclear staining and measured via fluorescence cytometry. n=3 with SD.
*p<0.05 comparing LNP concentration within a single time point. # p<0.05 comparing time points
with same LNP concentrations.
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Because differences in LNP stability were observed following drug loading,
BMDCs were cultured with 10-1 empty or ITE-loaded LNP for 24 hours and cells were
imaged using iCys laser-scanning cytometry. Representative iCys images, Figure 3.7a,
show that BMDCs cultured with ITE-loaded LNP exhibited higher LNP density per cell
(MFI = 1.52 x 106) than BMDCs cultured with empty LNP (MFI = 1.43 x 106).
Fluorescence cytometry corroborated iCys imaging as BMDCs cultured with ITE-loaded
LNP, compared to empty LNP, displayed significantly greater LNP+ frequency (ITEloaded 91.0%±0.2, empty LNP 85%± 1.0) and density (ITE-loaded 4,159.0 ± 80.0, empty
LNP 3,676.3 ± 107.7), as shown in Figure 3.7b. Empty LNP exposure in the presence of
ITE that was added directly to culturing medium did not lead to increased LNP uptake
(data not shown). Interestingly, mature BMDCs (CD11c+ MHCII high) exhibited greater
uptake of ITE-loaded LNP compared to immature BMDCS (CD11c+ MHCII low), and
non-BMDC (CD11c-MHCII-), as shown in Figure 3.8. Together, ITE-loading of LNP
resulted in increased LNP uptake by BMDCs with preferential acquisition by mature
BMDCs.
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Figure 3. 7 ITE-loaded LNP display increased uptake by BMDCs

Figure 3.7 ITE-loaded LNP display increased uptake by BMDCs.
Day 7 BMDCs were cultured with ITE-loaded and empty LNP for 24 hours and LNP uptake was
assessed by laser scanning cytometry (A) and fluorescence cytometry (B). Nuclei are labeled
with DAPI (blue) and LNP with Cy5 (red) in representative iCys images. n=3 per treatment
* p<0.05 between ITE loaded and empty LNP.
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Figure 3. 8 LNP uptake is BMDC maturation state-dependent.

Figure 3.8 LNP uptake is BMDC maturation state-dependent.
BMDCs were exposed to ITE-loaded LNP (10 -1) for 24hrs and analyzed by fluorescence
cytometry. LNP uptake after 24hrs was evaluated by BMDC maturation state where
CD11c+MCHIIhigh denote mature BMDCs (Red), CD11c+MHCIILow denote immature BMDCs
(Blue), and CD11c-MHCII- denote non-DCs (orange) and cell only control (Gray).
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ITE-loaded LNPs induce expression of AhR-responsive genes in BMDCs.
Dendritic cells display altered gene expression following TCDD-induced AhR
activation that is associated with tolerogenic or regulatory DC function (Bankoti et al.
2010a; Bankoti et al. 2010b; Jin et al. 2010; Quintana et al. 2010a; Simones and Shepherd
2011; Takenaka and Quintana 2017; Vorderstrasse and Kerkvliet 2001). Therefore, to
evaluate whether ITE-loaded LNP delivered the drug cargo to BMDCs and activated the
AhR resulting in gene expression similar to TCDD, BMDCs were exposed to 10 -1 ITEloaded LNP [100nM ITE], to 10-1 empty LNP with ITE [100nM] added directly to
culturing medium, or to TCDD [10nM]. Following 24-hour exposure, gene expression
was measured by RT-qPCR. As shown in Figure 9, compared to untreated BMDC
controls, the prototypical target gene induced by AhR activation, CYP1a1, was induced
equally in BMDCs exposed to TCDD (25-fold) and ITE-loaded LNPs (25-fold induction
vs control, respectively) while empty LNPs with ITE added exogenously to culture media
resulted in significantly less CYP1a1 induction (10-fold vs control). While IDO1
transcription was not significantly altered by any treatment group, IDO2 was
substantially upregulated in all treatments groups with greatest induction observed
following treatment with ITE-loaded LNP (TCDD: 7-fold; Empty LNP+ ITE: 8-fold; ITE
Loaded LNP: 36-fold). TGFβ3 was not significantly upregulated by any treatment other
than ITE-loaded LNP (9-fold).

Together, these data support that ITE-loaded LNP

delivered ITE cargo to dendritic cells resulting in the upregulation of previously defined
AhR-inducible immunoregulatory genes.
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Figure 3. 9 ITE-Loaded LNP exposure leads to increased gene expression consistent
with AhR activation

Figure 3.9 ITE-Loaded LNP exposure leads to increased gene expression consistent with AhR
activation. Day 7 BMDCs were exposed to TCDD, Empty LNP with externally added ITE
(100nM), and ITE-loaded LNPs (10-1) or left untreated for 24hrs. mRNA expression was assessed
via RT-qPCR analysis. Fold change is relative to cell only control and all genes are normalized to
β-actin reference gene. Genes analyzed include: cytochrome P450, family 1, subfamily a,
polypeptide 1 (Cyp1a1), indoleamine-2,3-dioxygenase 1 (IDO1), indoleamine-2,3-dioxygenase 2
(IDO2), transforming growth factor, beta 2 (Tgfb2). Data shown are representative of two
experiments (n=3). Asterisks indicate significance of p≤0.05.
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In vivo administration of ITE-loaded LNP results in their preferential deposition in the
spleen and acquisition by APCs.
To assess biodistribution of ITE-loaded LNP within lymphoid tissues in vivo,
C57Bl/6 mice received daily intraperitoneal injections (10uL/g/bw) for three consecutive
days. Single cell suspensions of spleen, mesenteric and popliteal lymph nodes, as well as
PBMCs were evaluated for LNP deposition by fluorescence cytometry. As shown in
Figure 10, LNP were not detected in blood or lymph nodes, however, LNP were present
in the spleen with twenty percent of live splenocytes having acquired LNP. Immune cell
populations of the spleen were then evaluated individually to determine subset-specific
LNP uptake. Antigen presenting cells, including macrophages and dendritic cells,
exhibited the highest LNP interaction with 43% of macrophage and 48% of DCs being
LNP+, while B cells and T cells had lower uptake frequencies at 22% and 15%,
respectively. Additionally, the evaluation of LNP density per cell, measured by mean
fluorescence intensity (MFI), established that DCs and macrophage acquired 1.5 times
more LNP (1500 MFI) than B cells (1000 MFI) and 3 times more LNP than T cells (500
MFI). Together, splenic APCs preferentially, but not exclusively, acquire LNPs following
in vivo intraperitoneal administration.
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Figure 3. 10 Splenic APCs preferentially take up LNPs in vivo following i.p.
administration

Figure 3.10 Splenic APCs preferentially take up LNPs in vivo following i.p. administration.
C57Bl/6 mice were treated i.p. with LNP at 10μl/kg/bw daily for three days and tissues were analyzed
for Cy5+ expression via fluorescence cytometry (A). The percent of LNP+ splenic immune cells was
evaluated as frequency and mean fluorescence intensity (MFI).
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Discussion
Activation of the AhR signaling pathway results in potent immunomodulatory
outcomes and is a highly promising target for treatment of immune-mediated
inflammatory diseases. Given that the prototypical AhR agonist, TCDD, is highly toxic,
non-toxic AhR ligands are of keen interest for therapeutic activation of the AhR. Nontoxic compounds, such as ITE, can be potent AhR activators; however, barriers currently
exist in the rapid metabolism and high dosing requirements necessary for biological
effects. Therefore, this study investigated the potential for ITE as a proxy for natural AhR
ligands, to be packaged and delivered using a PEGylated LNP carrier.
Numerous factors must be considered when determining drug delivery systems
for biological use. Importantly, the size of particle can substantially affect toxicity and
pharmacokinetics. Small particles are more reactive and toxic due to greater surface area
and are more likely to undergo renal clearance than larger particles (Albanese et al.
2012). Conversely, if particles are too large, they are quickly opsonized and cleared by
the mononuclear phagocyte system (Albanese et al. 2012). A combination of PEGylation
and maintaining a hydrodynamic diameter

<100nm should

pharmacokinetic properties with minimal toxicity.

provide optimal

We demonstrated that both

lyophilized and fresh PEGylated LNP maintained hydrodynamic ranges within the
optimal size of 100nm and were of spherical shape. While freeze-drying can result in
increased particle size compared to fresh LNP, the addition of Polysorbate 20 enabled
comparable size retention, likely by preventing vesicle aggregation that can occur
following lyophilization (Nohara et al. 2009). Maintaining optimal size of LNP following
freeze-drying is important because lyophilization is considered a highly relevant method
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to extend the shelf life of LNPs and drugs. Overall, the size and morphology of fresh and
lyophilized LNP suggests that these nanoparticles are highly suitable for biological
applications.
ITE is a very effective AhR activator; however, lower binding affinity and
increased metabolism require higher concentrations and more frequent administration for
effects similar to TCDD, the prototypical AhR ligand (Abron et al. 2018; Ehrlich et al.
2018; Henry et al. 2010; Quintana et al. 2010a). Therefore, we determined the efficiency
of ITE entrapment and release from LNP. Both fresh and lyophilized LNP exhibited high
entrapment efficiencies with a slight reduction observed following lyophilization. This
was to be expected as freezing and drying can result in structural LNP changes leading to
leakage of the drug during the hydration step (Desai et al. 2002; Yang et al. 2011).
Despite a small amount of ITE leakage after the freeze and dry process, a high percentage
of total ITE was retrieved in the final ITE-loaded LNPs using both preparation methods.
ITE also appeared to be contained within the lipid bilayer, which was supported by
thermogram analysis and lack of a burst effect in drug release studies. A burst effect, or
an initial, rapid release of drug within the first thirty minutes, is commonly attributed to
drug desorption from liposomal surfaces due to weak binding forces between the drug
and surface lipids. In the present study, ITE release peaked by 24 hours in vitro with no
burst effect present. This release pattern is in accordance with what has been observed for
other lipophilic molecules packaged within liposomal nanoparticles (Ramana et al. 2010)
and supports the likelihood of a steady diffusion of ITE across the lipid bilayer under
physiological conditions. Importantly, negligible release occurred before analysis,
suggesting that biological conditions, such as temperature and pH, initiated drug release.
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Together, the efficient entrapment and steady release of ITE with minimal metabolites
present suggests that LNPs formulated in the present study could deliver natural ligands
for continual, more concentrated release within target cells, and thus, more sustained
AhR activation.
AhR activation in DCs has potent immunomodulatory outcomes with
demonstrated ability to suppress inflammatory diseases (Benson et al. 2012a; Benson and
Shepherd 2010; Goettel et al. 2016; Quintana et al. 2010a; Yeste et al. 2012). It has been
reported that non-targeted LNP preferentially interact with antigen presenting cells,
including DCs and macrophage, and that LNP lipid composition can induce DC
maturation (Watson et al. 2012, Foged, 2004 #1119). Interestingly, in the present study,
mature BMDCs exhibited higher LNP density than both immature BMDCs and nonBMDCs. The LNP formulation did not appear to induce DC maturation as no changes in
frequencies of mature and immature BMDCs were observed compared to untreated
controls, suggesting that BMDC maturation state is an important factor in LNP uptake
efficiency. This outcome was unexpected as immature DCs are highly phagocytic while
DC maturation corresponds with reduced phagocytic activity (Mellman and Steinman
2001, Garrett, 2000 #1122), suggesting that phagocytosis is not the primary route for
LNP uptake by BMDCs. The neutralization of liposomal surface charge by PEGylation
and the use of phosphatidylcholine, which confers less charge than other phospholipids,
are highly effective at increasing in vivo stability, but can lead to poor cellular
interactions (Lee et al. 1993, Watson, 2012 #1111). However, the LNP in this study
maintained high interaction efficiency with BMDCs. Microscopy and fluorescence
cytometry confirmed that LNP and BMDCs were directly interacting in a manner
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suggestive of uptake, and not accumulation on the plasma membrane; however it is
noteworthy that this study did not definitively establish LNP internalization. To date,
multiple studies have reported that LNP are internalized by DCs, supporting the
likelihood of internalization accompanying the DC-LNP interactions observed in the
present studies (Watson et al. 2012,Soema, 2015 #1112). Interestingly, ITE-loaded LNP
showed greater cellular interaction than empty LNP, which may be explained by the
increased LNP rigidity observed following ITE entrapment. Previous reports have shown
that more rigid LNP are better internalized and result in more potent immune responses
(Watson et al. 2012, Foged, 2004 #1114). Together, LNP readily interact with BMDCs in
a maturation dependent manner and ITE-loaded LNP show greater uptake, suggesting
that AhR agonists will be delivered directly to BMDCs.
To further explore the effects of ITE-loaded LNP on DCs, gene transcription was
evaluated in BMDCs treated with ITE-loaded LNP, empty LNP, and empty LNP with
ITE-supplemented media compared to TCDD. Both TCDD and ITE-loaded LNP resulted
in equal induction of the prototypical AhR gene target, CYP1a1, supporting that ITE is
being delivered and activating the AhR. The lower CYP1a1 induction observed with ITE
added directly to culture media suggests that ITE-loaded LNP elicit more AhR activity
than free ITE. This is likely due to LNP enabling higher concentrations of ITE to
accumulate within cells and/or LNP packaging acting to protect against ITE degradation.
Strikingly, ITE-loaded LNP were more effective than TCDD in inducing both IDO2 and
TGFβ3, two genes tightly associated with TCDD-induced tolerogenic DCs (Simones and
Shepherd 2011, Bankoti, 2010 #683). This suggests that ITE-loaded LNP may provide a
route for greater induction of an immunoregulatory DC phenotype. Together,
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immunoregulatory gene expression profiles support that ITE-loaded LNP delivered high
concentrations of ITE to BMDCs and are potent AhR activators.
Nanoparticle

composition,

size,

and

surface

modifications

can

alter

biodistribution and lead to tissue-specific accumulation (Albanese et al. 2012, Love, 1990
#1115). Thus, LNP were evaluated for murine immune tissue deposition following
intraperitoneal injection. Interestingly, minimal accumulation was observed in all tissues
evaluated except the spleen. Substantial accumulation in the spleen was expected with
intraperitoneal administration of LNP as nanoparticles with hydrodynamic diameters of
~100nm are associated with splenic deposition and rigid, cholesterol-rich liposomes have
been shown to preferentially accumulate within the spleen (Capini et al. 2009, Love,
1990 #1115). Cell-specific uptake was also observed as splenic macrophage and DCs
showed higher LNP density than T cells or B cells, which was to be expected as APCs
have been shown to preferentially take up nanoparticles (Liu et al. 2013). This finding
may also be, in part, due to the organization of splenic tissue, where antigen presenting
cells are positioned closer to afferent lymphatics than both T cells and B cells, and likely
provides greater opportunity for LNP interaction with APCs (Calabro et al. 2016). The
future addition of targeting proteins such as anti-CD11c antibodies, a comprehensive DC
lineage marker, to the surface of LNP may reduce macrophage uptake and enable greater
cell specificity in vivo. Together, APCs acquire LNP at higher density than non-APCs
with preferential splenic accumulation observed following intraperitoneal administration.
Seminal work by Yeste et al. (Yeste et al. 2012) has provided promising proof of
principle for AhR agonist delivery in vivo using gold nanoparticles (auNP). However, key
concerns have surrounded auNP therapies within the biomedical field (Alkilany and
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Murphy 2010; Lewinski et al. 2008). At the cellular level, auNP exhibited significant
cytotoxicity with greater cellular uptake corresponding to increased disruption of
mitochondrial function, particularly within phagocytes (Liu et al. 2013). Recent studies
have also identified size and time-dependent toxicity of auNP where substantial
accumulation and low clearance rates were observed for three months in both the liver
and spleen (Li et al. 2018). Therefore, alternative, non-toxic nanoparticle carriers are
more desirable for pharmaceutical use. Additionally, while the present studies used
nanoparticles loaded with ITE as a proxy for natural AhR agonists, a broad range of
agonists exist and ligand-dependent effects are well documented (Boule et al. 2018a,
Ehrlich, 2018 #522, Benson, 2011 #1071). AhR ligands have a common theme of
hydrophobicity and planarity, suggesting that additional natural agonists could be
incorporated into the LNP platform similarly to ITE (Pohjanvirta 2011). It is thus highly
conceivable that this LNP platform could be tailored with ligands that elicit an AhR
response most efficacious for treatment of specific pathologies. Collectively, the present
study demonstrates that an alternative non-toxic, biodegradable LNP is an effective
carrier for AhR agonist delivery and may provide for a more biologically compatible
delivery system without sacrificing potency of AhR activation.

Conclusion
Liposomal nanoparticles exhibit high ITE entrapment efficiency, long-term
stability, and sustained ITE release under physiological conditions. LNP are
preferentially acquired by antigen presenting cells both in vivo and in vitro, with mature
DCs exhibiting greater LNP uptake in vitro. LNP are capable of delivering AhR agonists
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in order to activate the AhR and yield gene transcription equivalent to or surpassing, the
prototypical, but highly toxic AHR ligand, TCDD. In conclusion, the agonist-loaded LNP
developed in this study is a highly promising new route of therapeutic AhR activation.
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CHAPTER 4: CONCLUSIONS

Soon after the discovery of the AhR by Conney, Okey, and Nebert, a curious link
between the AhR and the immune system was identified when rodents exposed to a
known AhR agonist in vivo displayed severe thymic atrophy.

Since this initial

observation, AhR-mediated thymic atrophy has been seen in every animal species tested
to date. Numerous questions surround AhR-mediated thymic atrophy. Specifically, early
studies showed that AhR activation within the hematopoietic compartment was necessary
for AhR-mediated atrophy; however, the hematopoietic compartment is highly
heterogeneous and a key question that has remained since these early studies is whether
AhR expression within specific cell types of the hematopoietic compartment are
responsible for thymic atrophy. Additionally, as classes of AhR agonists expand beyond
exogenous compounds to include endogenous- and dietary-sourced ligands, some of
which have high therapeutic potential, important questions emerge regarding ligandspecific effects on the thymus. Therefore, the studies in this dissertation (1) show that
AhR activation within CD11c+ cells is necessary for TCDD-mediated thymic atrophy,
and identify ligand-specific effects within the context of thymic atrophy.
As our understanding of AhR-mediated immunomodulation expands, the AhR is
becoming a highly intriguing and promising target for novel therapeutics. Harnessing the
immunosuppressive potential of AhR activation, particularly within dendritic cells as
they are high AhR expressers and adopt a tolerogenic phenotype, could lead to regulation
of inflammation and autoimmune diseases. Proof of principle comes from seminal
research by the Quintana Laboratory at Harvard that showed systemic ITE exposure

could significantly lower disease scores in experimental autoimmune encephalomyelitis
(EAE), the mouse model of multiple sclerosis. Additionally, ITE loaded onto gold
nanoparticles in combination with a myelin peptide (MOG35-55) resulted in tolerogenic
DCs and T cells that significantly reduced the disease pathology. However, the use of
gold nanoparticles in therapeutic applications is entrenched with concerns regarding
safety and toxicity. Therefore, the studies in this dissertation (2) develop PEGylated
liposomal nanoparticles for delivery of AhR agonists, test ITE-loaded liposomal
nanoparticle interaction and AhR activation in murine bone marrow derived dendritic
cells, and evaluate liposomal biodistribution in mice.

Thymic atrophy is ligand-specific and TCDD-mediated thymic atrophy requires AhR
expression in CD11c+ cells.
The first goal of this study was to evaluate thymic atrophy by a select panel of
ligands and determine the role of AhR activation in CD11c+ DCs during TCDDmediated thymic atrophy. We demonstrated for the first time that administration of
endogenous ligand, ITE, p.o. or i.p., resulted in thymic atrophy characteristically similar
to TCDD albeit at higher doses, as indicated by reduced thymic weight and cellularity
due to substantial loss of the DP thymocyte population. Conversely, exposure to dietary
ligand, I3C, had an opposite effect with increased thymic cellularity observed by day 7.
The effects observed with I3C are quite surprising, and with interest growing in cancer
biology to promote or augment thymic function following severe immunosuppression
from chemotherapeutics and radiation, especially in children who do not have such
expansive T cell repertoires as adults, I3C may hold promise as a natural route to do so
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(Chung et al. 2014).
As the AhR signaling pathway is becoming an increasingly promising clinical
target with therapeutic immunomodulatory potential, alternatives to TCDD, which is not
considered suitable for therapeutic applications due to adverse toxicity, are of keen
interest within the field. ITE has shown extraordinarily promising therapeutic potential
in

treatment

of

autoimmune

diseases

such

as

experimental

autoimmune

encephalomyelitis (EAE) (Quintana et al. 2010c; Yeste et al. 2012); however, the
severe thymic atrophy reported here following systemic exposure to ITE is an adverse
effect that needs to be further considered when evaluating its therapeutic potential. One
avenue to potentially harness the therapeutic potential of ITE while bypassing this
adverse effect on the thymus is to contain ITE within a targeted delivery system. The use
of a delivery system may reduce the dosing regimen, the concentration of systemic ITE
exposure, and the adverse effects on the thymus.
Identification of the key cell type(s) mediating thymic atrophy following AhR
activation has been an unanswered question in AhR research for multiple decades. While
seminal work by Staples et al. (1998) showed that AhR activation within the
hematopoietic compartment is required for TCDD-induced thymic atrophy, work in this
dissertation has definitively established that AhR expression within CD11c+ cells, a
comprehensive, but not exclusive, lineage marker for DCs, is necessary for thymic
atrophy. Complete protection from TCDD-induced atrophy when mice lacked the AhR in
CD11c+ cells was an unexpected result. DCs in the thymus are a rare population,
comprising only ~1-2% of cells, while DP thymocytes, the population most affected by
TCDD, compose ~80% of cells; however, DCs constitutively express high levels of AhR
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with further inducible expression, while most T cell subsets and developing thymocytes
are low AhR expressers (Kreitinger et al. 2016). To ensure that CD11c in the thymus is
exclusive to DCs, we thoroughly performed CD11c staining on non-DC populations, and
did not detect CD11c expression outside of the DC lineage. We also used a broad panel
of conditional knock out mice to verify that AhR expression in thymic epithelial cells,
monocytes and macrophages, as well as thymocytes and mature T cells, did not result in
protection from thymic atrophy. Together, these results support that DCs are the key cell
type mediating the rapid, severe loss of thymocytes following exposure to TCDD. It is
necessary to mention that while CD11c is a comprehensive lineage marker for DCs, and
it could not be detected on non-DC populations within the thymus, CD11c can be
expressed by non-DC populations outside of the thymus, such as alveolar macrophages,
and the studies presented here did not conclusively establish that AhR expression in
CD11c+ cells specifically located within the thymus are sufficient for thymic atrophy.
Taken together, to the best of our knowledge, these in vivo studies are the first to identify
ligand-specific effects on thymic atrophy and to establish a requisite role for AhR
expression within CD11c+ cells for TCDD-mediated thymic atrophy.

ITE-loaded liposomal nanoparticles for therapeutic AhR activation
The second goal of this study was to develop and test a PEGylated liposomal
nanocarrier for delivery of natural AhR agonists.

We demonstrated that liposomal

nanoparticles entrap the natural AhR agonist, ITE, within the lipid bilayer with high
efficiency. While natural AhR agonists provide a promising alternative to the highly toxic
prototypical ligand, TCDD, substantial barriers currently exist in the rapid metabolism
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and degradation of natural AhR ligands. The entrapment of ITE within the lipid bilayer
resulted in little degradation product and provides a promising form of protection for
AhR agonists that are less stable than TCDD. Notably, studies presented here
demonstrate that natural ligands can have adverse consequences similar to TCDD, as ITE
induced severe thymic atrophy following systemic administration. This reinforces the
need for a delivery system that reduces systemic exposure for therapeutic AhR activation,
but also may suggest that ITE is not the most suitable natural compound. Importantly, the
platform developed within this study is well suited for incorporation of lipophilic
compounds and indolic compounds, such as indole-3-carbinol, may be optimal candidates
given their combination of AhR activating potential and absence of thymic atrophy. Shelf
life is another factor to consider for clinical utility of novel therapeutics. LNPs within this
study demonstrated release of ITE under physiological conditions with no leakage of ITE
being observed under storage conditions and the storage of ITE-loaded LNP for three
months did not reduce efficacy or interaction with BMDCs. Together, supporting that
LNP could be highly compatible with pharmaceutical use.
TCDD is considered the prototypical AhR ligand for its high binding affinity and
induction of dioxin-responsive genes, most notably CYP1a1 (Bankoti et al. 2010a;
Bankoti et al. 2010b; Simones and Shepherd 2011). ITE delivered by LNP were able to
induce CYP1a1 at the same levels as TCDD, while ITE added directly to culture media
resulted in lower induction. While the causes for this were not investigated in these
studies, reasons could include higher ITE concentrations accumulating within BMDCs,
reduced ITE degradation, or more sustained AhR activation by continual diffusion of ITE
from LNP. Overall, LNP may circumvent key issues with natural AhR agonists.
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In vivo experiments established that LNP accumulated within the spleen. This
was to be expected given the route of administration and the size of particle, as both
factors are optimal for splenic accumulation. While APCs of the spleen showed
preferential LNP interactions, it is important to note that the successful delivery of ITE in
vivo was not evaluated within these studies. However, in vitro studies indicate that ITE is
maintained within LNP and then slowly released with a majority of release occurring
within the first 24 hours, a timeframe that should accommodate LNP trafficking to
splenic APCs. Notably, LNP of 100nm can accumulate in the liver and the liver is a high
expresser of both AhR and CYP1a1 (Bozzuto and Molinari 2015; Çağdaş et al. 2014);
however, LNP trafficking to the liver was not evaluated in the present study. If
substantial LNP accumulation occurs within the liver, it has the potential to greatly
reduce LNP efficacy through substantial induction of xenobiotic metabolism. Moreover,
if a high concentration of ITE is being delivered to the liver, it may result in deleterious
effects on liver tissue similar to TCDD, such as congestive hepatophathy, or nutmeg
liver. While this was not evaluated in the present studies, the addition of PEG to LNPs
has been reported to reduce liver accumulation (Desai et al. 2002) and therefore may
reduce effects on the liver.

Future directions
The AhR provides a promising therapeutic target for treatment of immunemediated diseases. Compounds such as ITE have been highlighted as non-toxic
alternatives to TCDD for therapeutically activating the AhR; however, work here
suggests that the thymus is adversely affected by systemic ITE exposure. It remains of
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key interest to further assess the effects of natural ligands, including but not limited to
ITE and I3C, on the thymus, especially in light of our findings that I3C appeared to have
an opposite effect on the thymus by increasing, not decreasing, cellularity. While I3C is a
well-established AhR ligand, we did not evaluate the effects of I3C on the thymus for
AhR, or CD11c-AhR, dependence. To this end, it is necessary to develop higher
concentration formulations of lower-affinity agonists, such as ITE and I3C, which would
enable further testing in mouse strains on the AhRd allele background. Additionally,
while intraperitoneal injection of ITE-loaded LNP resulted in minimal thymic
accumulation, the three-day time point of these in vivo LNP exposures is not sufficient to
gauge thymic atrophy as peak atrophy occurs between 7-10 days post-exposure. Thus,
future studies with ITE-loaded LNP should consider longer time points for evaluation of
deleterious effects on the thymus.
Sex-dependent effects of AhR activation have been observed throughout my
doctoral training, are reported in previous publications, and remain of keen interest and
importance when evaluating AhR activation for therapeutic applications (Benson et al.
2012a; Nault et al. 2017). Key questions around sex-dependent effects include potential
differences in AhR expression levels, increased or reduced drug metabolism rates or
storage, and interactions with non-canonical proteins/pathways. AhR ligands are highly
lipophilic with bioaccumulation occurring in fatty tissues and non-targeted liposomal
nanoparticles have also been shown to accumulate within the liver (Lee et al. 2015a).
Interestingly, in murine livers, females express higher levels of AhR transcripts than
males; however, this has not yet been evaluated in immune cells or in the thymus.
Notably, hepatic transcriptomic studies in rodents show that TCDD exposure results in
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greater transcriptional variation in AhR-related genes within livers of males than females
(Lee et al. 2015a). The authors of this report suggest that the narrowed response in
females may be an adaptive function that enables females to better handle toxic
metabolites and to limit adverse toxicity. Interestingly, male rodents show increased
transcripts involved in oxidative stress and fatty acid biosynthesis after AhR activation.
This could conceivably impact the efficacy and adverse side effects of LNP-delivered
ligands in a sex-dependent manner; however, these possibilities remain to be evaluated.
Taken together, AhR immune responsiveness and toxicity differ between male and
female animals, which reinforces the importance of controlling for sex differences in both
mechanistic and therapeutic AhR studies.
Collectively this work provides novel discoveries that contribute significantly to
further our understanding of how the Aryl hydrocarbon receptor signaling pathway
regulates the immune system. The data presented in this dissertation provide the
foundation to direct future research studies that are expected to advance the basic,
biological function of the AhR in the immune system, while also promoting the exciting
potential of AhR ligand-loaded liposomal nanoparticles to become highly effective
therapeutics for the treatment of immune-mediated diseases.
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